



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>4</sup> :</b> C12Q 1/68, G01N 33/574 C12N 15/00	<b>A1</b>	<b>(11) International Publication Number:</b> WO 89/10412 <b>(43) International Publication Date:</b> 2 November 1989 (02.11.89)
<b>(21) International Application Number:</b> PCT/US89/01636 <b>(22) International Filing Date:</b> 18 April 1989 (18.04.89)  <b>(30) Priority data:</b> 182,501 18 April 1988 (18.04.88) US 297,188 13 January 1989 (13.01.89) US  <b>(71) Applicants:</b> APPLIED BIOTECHNOLOGY, INC. [US/US]; 80 Rogers Street, Cambridge, MA 02142 (US). WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH [US/US]; Nine Cambridge Center, Cambridge, MA 02142 (US).  <b>(72) Inventors:</b> WEINBERG, Robert, A. ; 25 Copley Street, Brookline, MA 02146 (US). MAZZARA, Gail, P. ; 10 Manchester Road, Winchester, MA 02890 (US). MORGAN, Jonathan, H. ; 3 Arrowhead Lane, Franklin, MA 02038 (US). MCKENZIE, Sara, J. ; 201 Ocean Street, Lynn, MA 01902 (US). MARKS, Paula, J. ; 93 Evans Road, Brookline, MA 02146 (US).		<b>(74) Agents:</b> GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, Two Militia Drive, Lexington, MA 02173 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB (European patent), IT (European patent), JP, KR, LU (European patent), NL (European patent), SE (European patent).  <b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> DETECTION OF NEU GENE EXPRESSION AND PRODUCTS  <b>(57) Abstract</b>  Nucleic acid probes reactive with regions of <i>neu</i> proto-oncogenes and/or oncogenes of mammalian origin are described, as are methods for their use in detecting the presence of <i>neu</i> proto-oncogenes and/or oncogenes in tumor cells. Antibodies specific for gene products encoded by the <i>neu</i> genes are also described. The nucleic acid probes and antibodies can be used to assess point mutational activation, amplification and overexpression of the <i>neu</i> genes and thus are useful in the diagnosis and prognosis of certain cancers.		

-1-

Detection of Neu Gene Expression and ProductsBackground

An increasing body of evidence implicates somatic mutations as causally important in the induction of human cancers. These somatic mutations may accumulate in the genomes of previously normal cells, some of which may then demonstrate the phenotypes associated with malignant growth. Such oncogenic mutations may include a number of different types of alterations in DNA structure, including deletions, translocations, amplifications and single nucleotide alterations. The latter, also known as point mutations, may frequently intervene in carcinogenesis, in that a variety of mutagenic chemicals induce such mutations. In addition, such

mutations may occur spontaneously as a result of mistakes in DNA replication.

Point mutations have been directly implicated in the causation of 10-15% of human tumors. These  
05 tumors carry oncogenes of the ras gene family, which differ from their normal cellular counterpart proto-oncogenes by the presence of a point mutation at one of several sites in these genes. These mutations represent qualitative changes in the tumor  
10 cell genome which distinguish these cells from normal cells and provide a basis for diagnosis of the genetic origin of a tumor under study. Identification of the mutations that have created active oncogenes may provide important diagnostic and  
15 prognostic clues for tumor development. For example, a number of mutations have been found to alter the 12th codon of the ras oncogenes, causing replacement of glycine, which is normally present, by any of a number of alternative amino acid res-  
20 idues. Such amino acid substitutions do not have equivalent effects; some substitutions (e.g., valine) create a potent transforming allele while others (e.g., proline) have only a limited effect on cellular phenotype. Thus, the identity of a par-  
25 ticular nucleotide substitution may be a strong determinant of the behavior of the tumor cell (e.g., its rate of growth, invasiveness, etc.). As a result, DNA probes of oncogene mutations have promise as diagnostic reagents in clinical oncology.  
30 Such probes are useful, however, only if a region of a gene of interest in which point

mutations are likely to occur has been identified. Unless identification of such a region has been made, it is impractical to use oligonucleotide probes of limited size (e.g., 10-20 nucleotides  
05 long) to scan an entire gene, which might well be 30,000 or more base pairs long; for example, if a 15-nucleotide probe were used to scan the entire length of a gene 33,000 base pairs long, 3000-5000 separate probes would be required.

10        Thus, although DNA probes of oncogene mutations have potential as diagnostic tools, they cannot be used effectively unless a discrete region of mutation in the gene, which is causally related to activation of the gene's oncogenic function, has  
15 been identified. Without such localization of the region of mutational activation, use of DNA probes specific for point mutations is impractical.

      The amplification and/or overexpression of proto-oncogenes have also been implicated in the  
20 causation of human tumors. The c-myc and N-myc proto-oncogene are amplified in small cell carcinoma of the lung and neuroblastoma, respectively. The N-myc proto-oncogene was found to be amplified 3-300 times in many stage II, III and IV tumors. The  
25 presence of the amplification of the N-myc proto-oncogene is always accompanied by an increased expression of the gene product though not necessarily proportional to the extent of amplification. More importantly the number of N-myc gene  
30 copies in primary untreated neuroblastomas is a clinically important prognostic factor that is

independent of stage (Seeger et al., N Engl J Med., 1985; 313:1111-6). There is a significant correlation between genomic amplification and rapid tumor progression. Thus, it is clear that detection  
05 of the amplification of a proto-oncogene or expression of its mRNA by nucleic acid hybridization techniques or detection of overexpression of an oncogene's protein product by immunological methods could have great prognostic value.

10 Disclosure of the Invention

This invention relates to assessment of cellular DNAs to determine whether they carry lesions or alterations, including amplification, in a neu gene which result in the overexpression or the activation  
15 of the proto-oncogene, and its conversion to an oncogene. Nucleic acid probes specific for nucleotide sequences of the region in which the activation mutation(s) resides, which can be used to determine the presence of an oncogene of the neu family are  
20 described, as are methods for their use. In addition, nucleic acid probes and monoclonal antibodies which recognize the neu proto-oncogene or neu gene encoded product and which can be used to determine the level of expression of the neu proto-  
25 oncogene mRNA and gene product, and methods for their use, are described.

It has been determined that the rat neu proto-oncogene, which encodes a protein resembling a growth factor receptor, is converted into an onco-  
30 gene by a single nucleotide alteration or point

mutation. This point mutation was initially seen in a rat neuroblastoma induced by transplacental exposure to a carcinogen (e.g., ethylnitrosourea) and found to affect the amino acid sequence of the transmembrane region of the p185 encoded by the DNA. That is, a valine present in the normal protein is replaced by a glutamic acid residue.

Nucleic acid probes used to assay for similar point mutations suspected to be present in seven additional neu oncogenes, each of which arose in a separate, independently induced tumor, demonstrated the presence of the same activating mutations in all seven neu oncogenes. The same amino acid substitution (glutamic acid replacing valine) resulted in these cells. Further assays with nucleic acid probes homologous to the neu gene demonstrates that the mutagen methylnitrosourea induces formation of nervous system tumors and activation of neu genes at the same position as shown to occur in the ethylnitrosourea-induced tumors.

The human homolog of the neu gene (also known as c-erbB2 or HER2) may achieve an oncogenic state through the action of a similar mechanism: alteration of a single nucleotide in the normal cellular DNA sequence (the proto-oncogene), resulting in activation of the oncogene. Due to sequence differences between the rat and human neu alleles it is not possible to generate the same mutation (valine to glutamic acid) with a single base change. This valine to glutamic acid substitution requires two base changes which makes it a very statistically

unlikely event. The effect of single base pair changes at this position in the human neu allele generating substitutions of amino acids other than glutamic acid is unknown but could be expected to occur.

Alternatively, the oncogenic activity of the neu proto-oncogene may be activated by gene amplification or other events that lead to the overexpression of the neu proto-oncogene.

The activating lesion found can be identified in the DNA of a variety of spontaneously arising human tumors through the use of nucleic acid probes constructed to be specifically reactive with the region of the human neu gene corresponding to the region in the rat neu oncogene known to contain the activating mutations. Identification in human tumor cells of the activating point mutation responsible for conversion of the proto-oncogene into the neu oncogene can serve as the basis for construction of nucleic acid hybridization probes useful in testing human tumor DNAs for the presence or absence of point mutations responsible for activation of neu oncogenes. These hybridization probes can be used in detecting the occurrence of the neu proto-oncogene and of the neu oncogene in cells and in determining the profile of oncogene activations in human tumor specimens. Such nucleic acid probes as well as standard nucleotide probes are described, as are methods for their use in detecting the presence or absence of neu oncogenes in tumor cells. In addition, nucleic acid probes for detecting

amplification and/or overexpression of the neu proto-oncogene or oncogene are described. Anti-bodies specific for the p185 protein encoded by the neu oncogene, which can be used to detect the  
05 occurrence of the neu oncogene, or proto-oncogene, are also described. Particular "capture" immunoassays are described for detection of the human neu antigen in biological fluids, such as human serum, plasma or urine or in normal, preneoplastic or  
10 neoplastic cells.

#### Brief Description of the Drawings

Figure 1 is a schematic representation of pSV2neu, created by inserting the neu gene cDNA indicated into the pSV2 expression vector.

15 Figure 2 presents electrophoretic gel patterns characteristic of cell lines containing pSV2neu constructions.

Figure 3 shows nucleotides 1968 to 2073 and the predicted amino acid sequence for the normal rat neu gene and the transforming rat neu gene.  
20

Figure 4 shows the nucleotide sequence of nucleic acid probes corresponding in sequence to a) the wild type (normal), b) the mutant neu version of the neu gene, c) DNA from DHFR G8, and d) a modified  
25 version of the mutant neu gene in which there is a T to G transversion.

Figure 5 shows electrophoretic gel patterns after hybridization of DNA from neu transfectants with nucleic acid probes.



Figure 6 shows electrophoretic gel patterns after hybridization of DNA from tumor cell lines and normal BDIX DNA with oligonucleotide probes.

05 Figure 7 shows electrophoretic gel patterns after probing of fourteen transfectants containing ten independent activated neu genes with either the oligonucleotide corresponding to the normal gene (proto-oncogene) (top) or the oligonucleotide corresponding to the transforming gene (on cogene)  
10 (bottom)

Figure 8 is a schematic representation of a full length neu cDNA clone constructed from cDNAs of two cervical carcinoma cell lines (ME180 and SW1710).

15 Figure 9 is a schematic representation of two human neu vectors, pMax neu and pMax delta neu, constructed by inserting the neu gene cDNA indicated into the pMax expression vector, and the pMax-Sph expression vector, respectively.

20 Figure 10 is a schematic representation of a hybridization probe created by inserting the portion of the neu gene indicated into the pGEM expression vector.

Figure 11 is a schematic representation of  
25 plasmid vector pLJdelta neu, created by inserting the neu gene cDNA indicated into the pLJdelta expression vector.

Figure 12 shows results of a capture immuno-  
assay in which lysates from a variety of human  
30 breast carcinomacell lines were tested for the presence of the neu antigen using the capture ELISA system. An anti-neu monoclonal antibody (TA-1) was

used to capture the p185 neu antigen and the anti-neu monoclonal antibody NA-3 labeled with biotin was used as the detection reagent.

Figure 13 shows results (microgram of tumor  
05 lysate vs. optical density) of a comparison between tumor lysate of a nude mouse tumor expressing neu (X-3-5) and tumor lysate of a neu negative tumor (3T3/ras), an anti-neu monoclonal antibody (NB-3) specific for the p185 neu antigen.

10 Figure 14 shows the results of an assay of cell lysates prepared from a normal piece of human breast tissue (2747-01-050) or a breast carcinoma (2427-01-050) and tested for the presence of neu antigen using the capture format. The assay was performed  
15 with an anti-neu monoclonal antibody designated TA-1 as the capture reagent and the monoclonal antibody BD-5 as the biotin-labeled detection reagent.

Figure 15 shows results of analysis of supernatant fluids from 18-3-7 cells (NIH3T3 cells  
20 transformed with the human neu gene and expressing the p185 protein on the cell surface), 3T3 ras cells (NIH3T3 cells transformed with the ras gene and not expressing the human p185 protein on the cell  
surface), and SK-BR-3 human breast carcinoma cells  
25 and culture media-DMEM supplemented with 10% fetal calf serum. In the capture immunoassay, an anti-neu monoclonal antibody, NB-3, was used as the capture reagent and an anti-neu monoclonal antibody, TA-1, labeled with biotin was used as the detection  
30 reagent.

Figure 16 shows results of a capture immunoassay using mice in which normal mouse sera, (T144),

sera from mice bearing tumors expressing the p185 protein (18-3-7 mouse), and from mice bearing tumors not expressing the p185 protein (3T3 (ras)) were assayed using an anti-neu monoclonal antibody, TA-1, as the capture antibody and an anti-neu monoclonal antibody, BD-5, labeled with biotin as the detection reagent.

Figure 17 shows the results of a capture immunoassay in which the anti-neu monoclonal antibody TA-1 was used as the capture reagent and BD-5 labeled with biotin was used as the detection reagent. Samples for analysis included normal human plasma and plasma from two breast carcinoma patients.

Figure 18 is a graphic representation of the average value of neu oncogene (units of neu) in plasma from three sets of human patients.

#### Detailed Description of the Invention

The neu oncogene was originally isolated from a rat neuroblastoma induced by transplacental exposure to the carcinogen ethylnitrosourea. The activating event was a single point mutation which caused a valine of the proto-oncogene to be replaced by a glutamic acid residue. The human homologue of the neu oncogene has also been cloned and its oncogenic potential can be activated by making the same mutation found in the activated rat allele, although two adjacent point mutations are required. In

addition, the human allele is oncogenic when over-expressed without any mutational changes. This is in direct contrast to the rat neu allele which when not mutated is non-transforming at any level of  
05 expression. A third mechanism may activate the human neu allele, truncation. When the amino terminal portion of the human neu proto-oncogene is deleted it then becomes transforming.

The involvement of proto-oncogenes in the  
10 genesis of human cancers is well documented. The mechanism by which proto-oncogenes contribute to the malignant process is varied. These mechanisms include alterations of the proto-oncogene's primary sequence or control of expression. Alteration of  
15 control of expression can be accomplished by increased expression of the pre-existing gene or by increasing the number of copies of the gene (gene amplification). Determination of the oncogene involved and the method of activation may have  
20 significant implications for diagnosis, prognosis and therapy.

Recently, the neu proto-oncogene has been shown to be amplified in human breast cancers. Neu was amplified from 2- to greater than 20 times in 30% of  
25 breast tumors. The presence of neu amplification was a significant predictor of both overall survival time and time to relapse (Slamon, et al., Science 1987; 235:177-182).

#### Mutational Activation

30 It is now known that cellular genes other than the ras genes can be converted into oncogenes by

point mutations. It has recently been shown that the rat neu proto-oncogene, which encodes a protein resembling a growth factor receptor, can also be converted into an oncogene by a single nucleotide alteration. Thus, it has been shown that the neu proto-oncogene (i.e., the nucleotide sequence present in the normal genome of normal non-tumor cells) can undergo mutational activation into its corresponding oncogene (i.e., the nucleotide sequence whose expression within a cell causes its conversion from a normal cell into a tumor cell) by a single nucleotide substitution. This point mutation, initially demonstrated in a rat neuroblastoma induced by transplacental exposure to ethylnitrosourea, has also been shown to occur in seven other neu oncogenes, each of which arose in a separate exposure, independently induced by ethylnitrosourea. Detection of the point mutations relied on the use of nucleic acid probes specific for the region initially shown to contain the activating mutation. In all cases, the same amino acid substitution resulted: a valine normally present in the transmembrane region of the encoded p185 protein was replaced by a glutamic acid residue. This finding suggests that nucleotide substitution at only a limited number of sites in the neu proto-oncogene will result in its becoming an active oncogene.

Transfectants which arose from DNAs from ten methylnitrosourea-induced nervous system tumors which contained activated neu genes have also been

shown to have the identical alteration in their DNA and are presumed to have the same sequence change as that present in the ethylnitrosourea-induced tumors, based on their differential hybridization to an  
05 oligonucleotide probe corresponding to the transforming gene. Thus, nucleic acid probes homologous to the neu gene have been shown to be able to detect activated neu genes in tumors induced by exposure to methylnitrosourea. In addition, this demonstrates  
10 that both mutagens cause activation of neu genes at the same position and that activated neu genes can arise in both BDIX rats (ethylnitrosourea-induced tumors) and Buffalo rats (methylnitrosourea-induced tumors).

15 Human versions of the rat neu genes have been isolated and are also referred to as c-erbB2 or HER2. Yamamoto, T. et al., Nature, 319:230-234 (1986); Coussens, L. et al., Science, 230:1132-1139 (1985). The DNA sequences of both the rat and the  
20 human clones predict a 1260 amino acid protein product of the neu gene.

Mutational activation of the human homologs of the rat neu genes, referred to here as the human neu oncogenes, may occur through a similar mechanism:  
25 single nucleotide substitution or point mutation in the human neu gene. It is highly likely that the single nucleotide substitution occurs in the region of the human neu proto-oncogene that corresponds with the region in the rat neu oncogene shown to  
30 contain the activating mutations. It is possible to determine the presence or absence of the activating

-14-

lesion in the DNA of a variety of spontaneously arising human tumors through the use of nucleic acid probes specifically reactive either with regions unique to the neu oncogene or with regions unique to the corresponding neu proto-oncogene. That is, hybridization probes can be constructed which will react (hybridize) with a nucleotide sequence occurring in either a neu oncogene or its corresponding proto-oncogene (but not in both).

Such probes can be used to test human tumor DNAs for the occurrence of a point mutation responsible for activation of the neu oncogene. For example, radiolabelled nucleic acid probes can be used in the Southern blot hybridization procedure to detect activation of the neu oncogene in human tumors of clinical interest.

#### Amplification/Overexpression

Amplification of the human neu proto-oncogene may be another mechanism for activating the oncogenic potential of the human neu proto-oncogene. The detection of the amplification of the human neu proto-oncogene can be accomplished using hybridization probes derived from any portion of the neu gene. These probes do not need to distinguish between the oncogene and proto-oncogene. Such methods have been used successfully to detect the amplification of the human N-myc gene in neuroblastomas.

Amplification of human oncogenes have been found in several tumor types. The best documented

is the amplification of the N-myc gene in neuroblastomas. This gene was found to be amplified 3-300 times in many stage II, III and IV tumors. More importantly the number of N-myc copies in  
05 primary untreated neuroblastomas is a clinically important prognostic factor that is independent of stage (Seeger et al., N. Engl. J. Med. 1985; 313: 1111-6). There is a significant correlation between genomic amplification and rapid tumor progression.  
10 There is also some evidence that overexpression of the N-myc gene in the absence of gene amplification has a similar correlation with prognosis. The amplification of oncogenes has been detected in a variety of other tumors. These include retino-  
15 blastoma (N-myc), acute promyelocytic leukemia, carcinomas of the colon, breast, lung, and stomach (c-myc) as well as many others.

Detecting amplification of the neu gene and/or overexpression of the neu gene product can be used  
20 to assay for the presence of cancer in mammalian cells. The amplification or overexpression can be measured at the DNA, RNA or protein level. In one embodiment of such an assay, nucleic acid (DNA or RNA) from the cells to be tested, can be combined  
25 with a radiolabelled nucleic acid probe which is complementary to a nucleotide sequence of the neu gene. The probe will hybridize with the complementary sequence of a neu gene present in the sample. The degree of such hybridization is  
30 measured using known techniques such as autoradiography followed by densitometry. An elevated



-16-

level of hybridization, as compared to a control, indicates amplification of the neu gene, which has been implicated in the causation of tumors. Thus, the level of hybridization is indicative of the  
05 presence of cancer in the cells. A 1.6 kilobase Eco RI restriction fragment of a neu gene as described below, as well as any other portion of the neu gene, can be used as the hybridization probe.

Detection of overexpression can also be done at  
10 the protein level. The p185 proteins encoded by neu oncogenes are different from those encoded by their corresponding proto-oncogenes, therefore it is also possible to develop serological reagents, such as polyclonal antibodies or monoclonal antibodies,  
15 which are specific for the altered or the normal amino acid sequences in such proteins. These reagents can be used to provide highly sensitive tests for the presence or absence of neu oncogenes by detecting the occurrence of the mutated or altered  
20 gene products they encode.

With serological reagents, the neu gene encoded protein can be detected using serological reagents on the surface of cells by immunohistochemical techniques and in various biological fluids using  
25 immunoassay techniques. For these tests, antibodies specific for the amino acid sequence, or a portion of the amino acid sequence of the neu encoded produce are employed.

Human tissue specimens (e.g., biopsy samples)  
30 can be tested for expression of the neu gene by immunohistochemical techniques such as the

immunoperoxidase staining procedure. Alternatively, immunofluorescent techniques can be used. In these tests, antibodies specific for the neu gene product are contacted with the tissue sample (cells) under  
05 conditions appropriate for binding of the antibody to the neu gene product. Preferred antibodies are specific for the extracellular domain of the neu gene encoded product. The level of binding to the cell (which can be determined by standard immuno-  
10 histochemical or immunofluorescent techniques), is indicative of the level of expression of the neu gene product.

The neu gene product can be detected in biological fluids by immunoassay techniques. These  
15 include competitive assays and immunometric (radio-immunometric or enzymetric) assays. A sample of biological fluid (i.e., blood, saliva) is obtained from the subject to be tested. The sample is contacted with antibodies specific for the neu gene  
20 encoded product under conditions which permit complexation of the antibody and the neu gene encoded product in the sample. The level of complex formation (antibody/antigen reaction) is indicative of the amount of neu gene encoded product in the  
25 sample. The amount of antibody-antigen complex can be measured by standard techniques. For example, in an immunometric assay a second labeling antibody is used to quantify the amount of antibody/antigen complex.

30 Immunometric assays by which human neu antigen has been detected in serum and plasma, as well as in

-18-

normal, preneoplastic and neoplastic cells, are described in Example 7A to 7C. The "capture" immunoassays were carried out as described in detail in the Examples and, in general, a capture immuno-  
05 assay for detection of human neu antigen in a human fluid carried out according to the present method includes:

a. forming an incubation mixture of a solid phase with a first monoclonal or polyclonal anti-neu  
10 antibody;

b. incubating the mixture under conditions appropriate for the anti-neu antibody to bind to the solid phase;

c. separating the solid phase from the fluid  
15 sample and eliminating (e.g., "blocking") any sites on the solid phase that do not contain anti-neu antibody;

d. forming an incubation mixture of the immunoabsorbent containing anti-neu antibodies with  
20 the human fluid containing neu antigen;

e. incubating the mixture under conditions and for a period of time sufficient for the human neu antigen in the fluid to bind to the immunoabsorbent;

e. separating the immunoabsorbent from the  
25 liquid sample;

f. incubating the immunoabsorbent with a second, labeled anti-neu monoclonal antibody; and

g. detecting the amount of label bound to the immunoabsorbent, using known techniques.

30 In particular, neu antigen can be detected using a forward capture immunoassay as detailed in Example 7. Briefly, polystyrene plates were coated

with an anti-neu monoclonal antibody, or a combination of anti-neu monoclonal antibodies, the purpose of which was to capture the neu antigen from biological specimens. Once coated, sites not bound to  
05 the capture antibodies were blocked with buffered bovine serum albumin. Samples containing, or suspected of containing, neu antigen were incubated and a second anti-neu antibody labeled with biotin was added. To detect the biotin, a streptavidin  
10 horseradish-peroxidase solution was added along with a substrate for the enzyme and the optical density of the product was measured. The quantity of neu antigen was determined by comparing the optical density of the samples with a predetermined relation-  
15 ship between the quantity of neu antigen standards and the optical density of these standards.

As a result of these assay methods, a ternary complex is formed which includes: 1) a first anti-neu antibody, 2) the neu gene product ("neu  
20 antigen") and 3) a second anti-neu antibody. This second antibody is labeled either before or after formation of complex. The label can be attached directly or indirectly to antibody using any standard method. For example, the antibody can be  
25 complexed with biotin. In immunoassays of this invention capable of detecting the neu antigen, the first antibody can be an anti-neu monoclonal antibody, a mixture of anti-neu monoclonal antibodies, or a polyclonal anti-neu antibody.  
30 The complex can be formed before it is immobilized onto a solid phase. In other embodiments, the complex can be immobilized on the solid phase at

-20-

the same time that it is formed. In preferred assays, the neu gene product is immobilized on an immunoadsorbent which specifically "captures" or binds the gene product. This immunoadsorbent is  
05 formed by affixing to it an antibody specific for an idiotope of the neu gene product. Thus, for most purposes, two different anti-neu antibodies are used to form the immunoadsorbent and the labeled antibody.

10 Capture assays may be performed in forward, reverse or simultaneous mode. In a forward capture assay for a neu gene product, an anti-neu antibody is affixed to a solid phase. A liquid sample to be tested is incubated with the immunoadsorbent.  
15 Incubation is maintained for a sufficient period of time to allow the neu gene product in the liquid sample to bind to its immobilized anti-neu antibody on the immunoadsorbent. After this first incubation, the solid phase immunoadsorbent is separated  
20 from the sample. The immunoadsorbent is washed to remove unbound antibody and interfering substances, such as non-specific binding proteins, which may also be present in the liquid sample. The immunoadsorbent containing neu antigen bound to im-  
25 mobilized antibody is subsequently incubated with a labeled anti-neu antibody to form a ternary complex of: immobilized antibody-neu antigen-labeled antibody. The incubation is carried out for a period of time and under conditions sufficient to ensure  
30 binding of the labeled anti-neu antibody to the neu antigen. After the second incubation, another wash

may be performed to remove unbound label from the solid phase immunoabsorbent. The labeled anti-neu antibody bound to the solid phase immunoabsorbent is then measured, and the amount of label detected  
05 serves as a direct measure of the amount of neu antigen present in the liquid sample.

The sandwich immunoassays may also be performed in reverse and simultaneous modes. In reverse modes, an incubation mixture is formed of the liquid  
10 sample to be tested containing neu antigen and a soluble labeled anti-neu antibody. The mixture is incubated, then contacted with a solid phase immuno-adsorbent containing the same or different anti-neu  
antibody. After another incubation, the immuno-  
15 adsorbent is separated from the mixture and the label bound to the immunoabsorbent is taken as an indication of the amount of neu antigen in the liquid sample.

In the simultaneous mode, an incubation mixture  
20 is formed of the liquid sample containing neu antigen to be measured, labeled anti-neu antibody and the solid phase immunoabsorbent. After appropriate incubation to form a ternary complex, the solid phase immunoabsorbent is separated from the mixture  
25 and the label associated with the immunoabsorbent is measured to give an indication of the amount of neu antigen in the liquid sample.

#### Tumor Therapy

The antibodies specific for the neu gene  
30 encoded product can be used to treat tumors. For

therapy, the antibodies can be used alone in passive immunotherapy or as components of immunotoxins. In passive immunotherapy, an anti-tumor amount of monoclonal antibody is administered in a physiologically acceptable vehicle (e.g., normal saline) to a patient afflicted with a tumor which expresses the neu gene product (see Example 8). For example, antibodies specific for the extracellular domain of the neu gene product can be used for tumor therapy.

05

10 For immunotoxin therapy, the antibody can be linked to an anti-cancer pharmaceutical or a cytotoxin to form an immunotoxin. Various pharmaceutical or cytotoxic agents can be covalently or noncovalently coupled to the antibodies. Examples of useful

15 therapeutic agents include: radioactive compounds (e.g., isotopes of Boron and Rhenium); agents which bind DNA, such as alkylating agents or various antibodies (e.g., daunomycin, adriamycin, chlorambucil); anti-metabolites (e.g., metho-

20 trexate); and inhibitors of protein synthesis (e.g., diphtheria toxin and toxic plant proteins).

For the therapeutic uses described, the antibodies against the neu gene encoded product can be designed as chimeric antibodies. Chimeric anti-

25 bodies have variable regions (antigen binding regions) of nonhuman (e.g., murine) origin and constant regions of human origin. Because they are predominately human, chimeric antibodies are less immunogenic in humans which can help overcome

30 problems associated with administering foreign proteins to humans.

The invention is further illustrated by the following Examples.

Example 1: Isolation of neu cDNA clones and neu gene products

05      A. The neu gene family

Exposure of perinatal BDIX rats to a single dose of the alkylating agent ethylnitrosourea leads to a high incidence of neuroectodermal tumors. Rajewsky, M.F. et al., In: Origins of Human Cancer, 10 Cold Spring Harbor Laboratory, 709-726 (1977); Rajewsky, M.F., In: Recent Results in Cancer Research 84:63-76 (1983). Up to 95% of animals mutagenized transplacentally after the fifteenth day of gesta- 15 tion or injected directly with ethylnitrosourea up to ten days after birth will develop central and peripheral nervous system tumors after a dose- and strain-dependent latency time. These tumors and the cell lines derived from these tumors display the characteristics of a wide variety of neural and 20 glial cell types. Schubert, D., Nature, 249:224-227 (1974).

DNA isolated from four independently derived tumor cell lines of this type contains activated oncogenes which can be detected in an NIH 3T3 focus 25 forming assay. The majority of oncogenes detected in this assay have been shown to be genetically altered versions of one of the three closely related



-24-

ras genes (Varmus, 1984). However, the gene transferred from these neuro/glioblastomas is unrelated to the ras genes and has been designated neu.

Neu was first recognized to be a distinct gene  
05 by its association with the 185,000 dalton tumor antigen, p185, which is displayed on the surface of transfected cells. Neu is related in DNA sequence to the erbB gene, which encodes the epidermal growth factor (EGF) receptor, and antisera raised against  
10 the EGF receptor show some cross-reactivity with p185. However, detailed analysis has shown that neu bears only limited homology to erbB and that the two genes reside on different chromosomes. Schechter, A.L. et al., Science, 229:976-978 (1985). Thus, the  
15 neu gene is related to, but distinct from, the gene which encodes the EGF receptor.

cDNA clones of the neu oncogene have been isolated from cell lines transformed by this gene. Bargmann, C.I. et al., Nature, 319:226-230 (1986).  
20 Human versions of the same gene have also been isolated and termed variously c-erbB2 or HER2. The DNA sequences of these rat and human clones predict a 1260 amino acid protein product of the neu gene which is colinear with and 50% identical to the  
25 predicted amino acid sequence of the EGF receptor. By analogy to the EGF receptor, the neu product appears to be a transmembrane protein consisting of a cysteine-rich extracellular region of 650 amino acids, a transmembrane domain, and an intracellular

portion of 580 amino acids consisting in part of a tyrosine kinase domain.

Biochemical studies of the p185 protein support these conclusions. p185 is glycosylated and accessible to antisera in intact cells, which is consistent with its being localized at the cell surface. It also has an associated tyrosine specific protein kinase activity. p185 does not, however, bind EGF and thus appears to be the receptor for an as yet unidentified growth factor.

B. Isolation of clones of normal and transforming alleles of the rat neu gene

Biologically active genomic clones of normal and transforming alleles of the rat neu gene have recently been isolated. Hung, M.-C, et al., Proceedings of the National Academy of Sciences, U.S.A., 83:261-264 (1986). Structural comparison of these clones revealed no evidence of gross rearrangements, suggesting that subtle genetic alterations were responsible for activation of the neu oncogene. Comparable levels of p185 were shown to be expressed in nontransformed cell lines containing the normal allele and in transformed cell lines containing the mutant allele, suggesting that the alteration responsible for the activation of neu did not lead to deregulation of expression of the gene. Such results implicate a transforming lesion within the encoded protein p185, which should be represented in cDNA versions of the gene.

C. Comparison of cDNA clones of the normal neu gene and transforming cDNA clones

To determine the effect of the alteration responsible for activation of the neu gene, a  
05 comparison was made of the previously isolated transforming cDNA clone, DNAs from three other ethylnitrosourea-induced activations of the neu gene and a cDNA clone of the normal allele of neu.

Isolation of a normal neu cDNA clone

10 It was first necessary to isolate a normal neu cDNA clone. To do so, a cDNA library was constructed using RNA from the cell line DHFR G8. Hung, M.-C., et al., Proceedings of the National Academy of Sciences, U.S.A., 83:261-264 (1986). The  
15 DHFR cell line was made by transfecting a genomic cosmid clone containing a complete normal neu gene from the BDIX strain of rat into NIH 3T3 cells. These cells express high levels of the neu gene product, p185, and a high level of the neu RNA  
20 transcribed from the transfected gene. cDNA clones were made by the S1 snapback technique, tailed with dCTP using terminal transferase, and inserted into dG-tailed pBR322 at the PstI site. Thirty recombinant plasmids reactive with neu probes were iso-  
25 lated.

These plasmid clones were compared by restriction mapping to a full length cDNA clone of an activated neu oncogene. While these normal cDNA clones have common sequences with the previously  
30 identified transforming cDNA clones, none contained the entire coding region of neu. A clone containing the entirety of the neu coding region was con-

structed, however, by in vitro recombination of two partial, overlapping clones which share a unique NaeI site. The 5' end of the resulting clone was sequenced to verify the presence of the initiation  
05 codon for the neu-encoded p185 protein.

This normal neu clone was inserted into the pSV2 expression vector to create pSV2neuN, as shown in Figure 1. Mulligan, R.C. et al., Nature, 277: 108-114 (1979). A transforming neu cDNA clone  
10 derived from the B104-1-1 cell line, which is a secondary transfectant of an activated rat neu gene, was inserted into pSV2 to create a plasmid designated as pSV2neuT (Figure 1). pSV2neuT was highly active in a focus-forming assay on NIH 3T3 cells or  
15 Rat 1 fibroblasts. This assay measures the ability of DNA molecules that have been introduced into cells by the transfection to convert such cells, growing in monolayer culture to a transformed state, causing descendants of these cells to form a cluster  
20 or focus of morphologically transformed cells in an area of the cell monolayer. However, when the normal neu cDNA, also inserted into the pSV2 vector, was transfected into NIH 3T3 cells using identical conditions, no foci were observed.

25                   Comparison of p185 production by trans-  
                    formed and nontransformed cells

Cell lines containing the pSV2neuN or pSV2neuT plasmids were isolated by cotransfection with pSV2neo (referred to hereafter as the neo-r marker)  
30 and selection of G418. Southern, P.J. and P. Berg, Journal of Molecular and Applied Genetics, 1:327-341 (1982). Cell lines expressing the pSV2neuT

construct were morphologically transformed and refractile; those containing pSV2neuN were flat and nontransformed in morphology. These cell lines were metabolically labeled with  $^{32}\text{P}$  orthophosphate and  
05 their lysates incubated with a monoclonal antibody that specifically precipitates the rat neu gene product. As shown in Figure 2B, lanes c, d, and i, the levels of labeled p185 were comparable in the transformed and nontransformed cells. These results  
10 are consistent with earlier work suggesting that neu has been activated by a mutation in the coding region of the gene rather than one which deregulates expression. Hung, M.-C. et al., Proceedings of the National Academy of Sciences, U.S.A., 83:261-264  
15 (1986).

Example 2: Genetic analysis of the neu gene

A. Identification of the DNA sequences responsible for neu gene activation

Identification of sequences responsible for the  
20 transforming activity of the pSV2neuT clone was carried out by using recombinants between this clone and the pSV2neuN clone carrying the normal allele.

The recombinants were constructed by ligation of appropriate cloned DNA segments. Figure 1 shows the  
25 structure of a series of clones which delineate the region of neu that carries the activating mutation. The structure of each recombinant clone shown was verified by restriction mapping. In each case, at least two independent plasmid isolates were tested  
30 for the ability to morphologically transform NIH 3T3

cells. All recombinant clones were cotransfected with the neo-r marker and the morphology of the resulting G418-resistant colonies was scored. Morphologically nontransformed colonies were tested  
05 to ensure that they were expressing structurally intact p185 protein from the acquired cDNA clones.

Clones pSV2neuF and pSV2neuB, which contain the first 719 and 1899 nucleotides, respectively, of the transforming clone fused to the remaining sequences  
10 of the normal clone (Figure 1), were not transforming, although they did direct the synthesis of p185. Clone pSV2neuH, which contained transforming neu sequences from the 5' end of the gene up to nucleotide 2387 and normal neu sequences thereafter, gave  
15 foci upon transfection and yielded transformed colonies indistinguishable from those generated by the parental pSV2neuT clone. pSV2neuC was also transforming. It contained an XbaI fragment from nucleotide 2337 to nucleotide 3534 of the normal neu  
20 gene, which replaced the corresponding portion of the transforming cDNA. These results indicate that the normal cDNA and the transforming cDNA differ in a sequence between nucleotides 1899 and 2337 and that the presence of this sequence in the transform-  
25 ing clone is necessary for transformation.

In order to prove that this sequences is also sufficient for transformation, the reciprocal constructs pSV2neuTN and pSV2neuNT (Figure 1) were constructed and tested by transfection into NIH 3T3  
30 cells and Rat 1 fibroblasts. pSV2neuTN contained the entire transforming cDNA with the exception of

nucleotides 1899 to 2387, defined by NdeI and BgII sites, which are derived from the normal neu clone. pSV2neuNT contained the entire normal neu cDNA sequence except for the corresponding 488 nucleotides, which were replaced by those from the transforming clone. In parallel experiments, pSV2neuNT gave comparable numbers of foci to pSV2neuT, the parental transforming clone; pSV2neuTN, pSV2neuN, and mock transfected controls yielded no foci.

05

10 These experiments demonstrate that the essential genetic differences between the normal and transforming clones reside within this 488 nucleotide fragment.

The data shown in Figure 2 support these

15 conclusions. G418-resistant cell lines isolated by cotransfection of the pSV2neu plasmids and the selectable neo-r gene are shown in Figure 2A. Lines containing pSV2neuTN or pSV2neuN are morphologically flat and indistinguishable from lines transfected

20 with the neo-r gene alone. In contrast, cells containing pSV2neuNT and pSV2neuT are highly refractile and very similar to one another in morphology. These cell lines were metabolically labeled with <sup>32</sup>P-orthophosphate and the resulting lysates incubated with anti-p185 monoclonal antibody 16.4.

25 Drebin, J.A. et al., Nature, 312:545-548 (1984). Figure 2B shows the levels of p185 expressed in representative cell lines containing pSV2neuN (lanes c and d), pSV2neuT (lane i), pSV2neuTN (lanes e and

30 f), and pSV2neuNT (lanes g and h). Lysates from DHFR G8 and B104-1-1 cells (lanes b and j), the

cells lines from which the normal and transforming  
cDNAs were isolated, were also analyzed. Although  
individual cell clones show a wide range of p185  
levels, it is clear that there are similar ranges of  
05 p185 expression in both the normal and transformed  
cells. No p185 is found in lines transfected with  
the neo-r marker clone alone (lane a). Thus, the  
differences in these cells must be accounted for by  
intrinsic differences in the properties of the p185  
10 proteins that they express.

B. Definition of the mutation distinguishing  
the normal neu allele and the activated neu  
gene

The complete DNA sequence of the coding region  
15 of the transforming neu cDNA has been determined.  
Bargmann, C.I. et al., Nature, 319:226-230 (1986).  
To define the precise mutation that distinguishes  
the two alleles, the DNA sequence of the region  
between nucleotides 1899 and 2387 was determined for  
20 the normal neu cDNA. Only a single difference was  
found between this sequence and that previously  
determined for the transforming clone. At nucleo-  
tide position 1012 there is an A in the oncogene  
clone, while the normal clone carries a T in this  
25 position. As a result, the predicted amino acid  
present at residue 664 of the encoded p185 is  
affected; a valine found in the normal protein is  
replaced by a glutamic acid in the oncogenic ver-  
sion. Figure 3 shows the DNA and predicted amino  
30 acid sequence of nucleotides 1968 to 2073 for both  
the normal neu gene and the transforming neu gene.



The presumed mutation falls within the putative transmembrane domain of the neu gene product, p185.

Genomic clones of normal and transforming alleles of neu have been previously isolated. These  
05 clones were used to independently verify the nucleotide difference seen in the cDNAs. Such corroborative data served to exclude the possibility that the observed difference in the cDNAs arose during cDNA cloning. Sequencing of subclones of the genomic  
10 versions of the two alleles confirmed that the same T to A substitution was present in these genomic clones. This indicates that the mutation, a T to A transversion, arose somatically during creation of the B104 neuroblastoma tumor or cell line.

15 Example 3: Activation of neu oncogene

A. Determination of activation of independent neu oncogenes

Earlier results had shown that DNAs prepared from four out of six neuro/glioblastoma cell lines  
20 displayed activated neu oncogenes in a NIH 3T3 focus assay. Shih, C. et al.: Nature, 290:261-264 (1981). These six cell lines had been derived by transplacental mutagenesis of BDIX rat embryos with ethylnitrosourea. These independent activated neu  
25 genes were evaluated to see if they contain the same activating mutation. DNAs from transfectants containing these neu genes were hybridized with nucleic acid probes which would recognize preferentially one or the other allele of the neu gene.  
30 This technique has been successful in identifying

various activated alleles of ras genes. Bos, J.L. et al., Nature, 315:726-730 (1985); Zarbl, J. et al., Nature, 315:382-385 (1985).

05 Nucleic acids corresponding in sequence either to the wild type or the mutant neu version of the neu gene were synthesized. The sequence of these two 20-mers is given in Figure 4. These 20-mers were then hybridized under stringent conditions (2 degrees below the calculated  $T_m$  of a perfect duplex) to dried agarose gels containing DNAs which had been digested with appropriate restriction endonucleases. The 20-mer corresponding to the wild type sequences hybridized approximately ten times as well to pSV2neuN as it did to pSV2neuT. In contrast, the 15 nucleic acid whose sequence derived from the transforming allele preferentially hybridized to pSV2neuT by the same factor.

DNA was isolated from transfectants carrying the four independently activated neu oncogenes described above and cleaved with HindIII. The 20 resulting fragments were resolved on a 1% agarose gel. The agarose gels were incubated under conditions identical to those used in analysis of the cloned DNAs described above shown in Figure 4. DNA 25 from DHFR G8, which contains about 50 copies per genome of the normal genomic neu gene, was included as a control.

Figure 5A shows hybridization of the transfectant DNAs with the nucleic acid corresponding to the 30 wild type sequence. A strong signal appears in DHFR G8 DNA, which has introduced copies of the normal

neu gene (lane b). Considerably weaker signals can be seen in lanes containing the neu-transformed transfectant DNAs (lanes c-f) and in untransfected NIH 3T3 cells (lane a). Figure 5B shows an identical gel prepared in parallel probed with the nucleic acid containing the mutant sequence. DHFR G8 DNA reacts only weakly with this probe (lane b) but all neu-transformed transfectant DNAs (lanes c to f) yield strong signals with this probe. The transfectant DNA shown in lane d has a smaller neu-homologous HindIII fragment than the other transfectants due to truncation of the transfected gene at the 3' end.

A low level of reactivity between the wild type probe and the transfectants is probably due to cross-reactivity of the probe, since it is comparable to the signal seen upon analysis of cloned pSV2neuT DNA with the same probe (compare Figure 4 lanes b and d with lanes c-f in Figure 5A and 5B).

In order to control for differences in signal intensity due to DNA loading and transfectant copy number, the gel in 5B was stripped of probe and rehybridized with a nucleic acid probe from a different part of the neu gene. The transfectant cell lines may contain different copy numbers of the rat neu gene due to variable amplification during the process of transfection. The results of this hybridization are shown in Figure 5C. Comparison of corresponding lanes in Figures 5A, B, and C shows that DNAs of all neu oncogene transfectants exhibit stronger hybridization with the mutant probe than

with the wild type probe, and that the extent of their hybridization with the mutant probe correlates well with the copy number of the neu gene present in the various DNAs.

05        Although these data strongly suggest that all of the activated neu genes studied have alterations at the same nucleotide position, it was not clear whether the mutations involved the same T to A transversion in all cases. A T to G transversion  
10 might give the same pattern of hybridization, since it would cause an A/G mismatch with the wild type nucleic acid and a relatively stable G/T mismatch with the mutant nucleic acid. To address this possibility, a third 20-mer was synthesized with the  
15 sequence shown in Figure 4. This nucleic acid was incubated under hybridizing conditions with the gel analyzed in Figure 5A after the initial probe had been removed. This nucleic acid did not hybridize preferentially to the transfectant DNAs under  
20 stringent conditions (Figure 5D). Thus, the alteration in each of these activated neu genes is probably the same T to A transversion.

      That the point mutation was generated during tumorigenesis and thus did not reflect preexisting  
25 polymorphism in the rat genome or activation during the transfection process was also confirmed. DNA was isolated from BDIX rat liver and from the four rat tumor cell lines which were derived from BDIX rats and yielded activated neu genes in a trans-  
30 fection assay. Duplicate gels were probed either with the wild type or the mutant nucleic acid

(Figure 6). BDIX liver DNA reacts well with the wild type but not with the mutant nucleic acid (Figure 6, lanes a and f). In contrast, the four tumor cell lines react only with the mutant nucleic acid (Figure 6, lanes b-e and i-l). This demonstrates that the T to A transversion at nucleotide 2012 arose in the generation of the tumor or tumor cell lines. It also seems that the tumor cell lines are hemizygous or homozygous for the activated allele of the neu gene. Loss of the normal allele may have occurred during tumorigenesis or in passage of the tumor cell lines. A similar loss or under-expression of the normal ras alleles has been observed in several tumors and tumor cell lines that contain oncogenic versions of these ras genes. Capon, et al. Nature, 304:507-513 (1983); Guerrero, I et al., Proceedings of the National Academy of Sciences, U.S.A., 82:7810-7814 (1985).

Multiple independent activations of neu  
Chemical carcinogenesis, though provoked by apparently randomly acting agents, often results in specific genetic changes in the resulting tumor cells. Neu appears to be activated by the same nucleotide change in each of the four of the transforming neu alleles analyzed. Each of these alleles was isolated from a neuro- or glioblastoma that arose from transplacental exposure to the alkylating agent ethylnitrosourea. Schubert, D. et al., Nature, 249:224-227 (1974). Neu is also activated at the same residue in four independent nervous

-37-

system tumors induced by the related alkylating agent methylnitrosourea.

Similarly, extensive study of methyl-nitrosourea-induced mammary carcinogenesis in Buf/N rats has shown that among nearly 100 independent resulting tumors, all contain H-ras oncogenes activated by the identical G to A transition at residue 35. Sukumar, S. *et al.*, *Nature*, 306:658-661 (1983); Zarbl, H. *et al.*, *Nature*, 315:382-385 (1985). Other examples of specificity of activation include dimethylbenzanthracene-induced papillomas with activated H-ras genes in genetically susceptible Sencar mice and thymic lymphomas induced by gamma irradiation or methylnitrosourea, which yield transfectable K-ras and N-ras oncogenes, respectively. Balmain, A. and I.A. Pragnell, *Nature*, 303:72-74 (1983); Guerrero, I. *et al.*, *Proceedings of the National Academy of Sciences, U.S.A.*, 81:202-205 (1984). The K-ras oncogenes detected in the former case appear to have the same activating mutation in at least three out of four tumors examined. It is interesting to note that the administration of the same mutagen, methyl-nitrosourea, under different conditions leads to the specific activation of H-ras in mammary tumors, N-ras in thymic lymphomas, and neu in neuroectodermal tumors. Guerrero, I. *et al.*, *Science*, 225:1159-1162 (1984).

The carcinogen which induces each of these tumors must initially inflict widespread damage to the cellular DNA. The final mutation detected is,

however, highly specific. Clearly, strong biological forces must act during multistep carcinogenesis to select the outgrowth of cells bearing the genetic lesions observed in the ensuing tumors. It appears  
05 that only a small proportion of cellular genes can be converted into biologically active oncogenes. Within one of these genes, only a few of many possible mutations will yield an actively transforming oncogene. The relatively rare mutations which do  
10 generate oncogenes are enriched first because they must confer a selective advantage to the tumor, and later because they can be detected in the focus-forming assay.

The repeated appearance of a specific lesion in  
15 one tumor type suggests the presence of additional forces selecting among the possible activating mutations. The nature of the activating mutation must be strongly influenced by the chemical reactivities of the carcinogen. For example, different mutagens used to induce thymomas lead to  
20 different activated genes in the resulting tumors. Similarly, mammary carcinomas induced by dimethylbenzanthracene contain a different specific alteration from those induced by methylnitrosourea.

25 The reactivity of ethylnitrosourea, the agent which induced the described neuroblastomas, allows it to form a number of different adducts in DNA. Singer, B. and J.T. Kusmierek, Annual Review of Biochemistry, 52:655-693 (1982). Among these, an  
30 adduct causing G to A transition mutations is well described. Rajewsky, M.F., Recent Results in Cancer

-39-

Research, 84:63-76 (1983). Such mutations have been found repeatedly as the activating lesions in the H-ras oncogenes of mammary carcinomas induced by the related carcinogen methylnitrosourea. Zarbl, H. et al., Nature, 315:382-385 (1985). The presently described mutations are, however, T to A transversions, the creation of which must be explained by alternative mechanisms involving another one of the many adducts formed after administration of these alkylating agents. This type of mutation is not without precedent: two other ethylnitrosourea-induced mutations isolated after germ-line mutagenesis of mice has also been shown to be T to A transversions. Popp, R.A. et al., Genetics, 105:157-167 (1983); Lewis, S.E. et al., Proceedings of the National Academy of Sciences, U.S.A., 82:5829-5831 (1985). An N-ras oncogene isolated from a methylnitrosourea-induced lymphoma has been found to be activated by a C to A transversion suggesting that several different adducts induced by alkylating agents can lead to mutations. Guerrero, I. et al., Proceedings of the National Academy of Sciences, U.S.A., 82:7810-7814 (1985).

Example 4: Detection of neu oncogenes using nucleic acid probes

A. Examination of tumor DNAs from Buffalo rats with nucleic acid probes homologous to the neu gene

Sukumar and Barbacid (National Cancer Institute, Bethesda) have isolated ten



methylnitrosourea-induced nervous system tumors of Buffalo rats which contain activated neu genes. Transfectants which arose from these tumor DNAs were assessed to determine whether the mutation in these  
05 neu genes was identical to that found in the tumors previously described.

This was carried out in the following manner: Fourteen transfectants containing ten independent activated neu genes are shown in Figure 7 (tracks  
10 1-14). Duplicate gels were probed with the nucleic acid probes described above. That is, they were probed either with the normal nucleic acid (Figure 7, top) or the nucleic acid corresponding to the transforming gene (Figure 7, bottom). NIH DNA  
15 (track N), DHFR G8 DNA (track G) (high copy of the normal neu gene0, B104-1-1 DNA (track B) (high copy of the transforming neu gene) and two Buffalo rat tumors which do not contain active neu genes (tracks c1 and c2) were included as controls. All of the  
20 tranfected neu genes bore the identical alteration as that in B104-1-1 DNA, the cell line from which the transforming neu cDNA clone described above was derived. Based on their differential hybridization to the nucleic acid corresponding to the trans-  
25 forming gene, the transfected neu genes are presumed to have the same sequence change as the B104-1-1 neu gene. These results provide ten independent examples of activated neu genes detected with the nucleic acid; demonstrate that a second mutagen,  
30 methylnitrosourea, leads to the activation of neu genes at this position in a similar way as

ethylnitrosourea; and demonstrate that activated neu genes arise in Buffalo rats as well as BDIX rats.

B. Oligonucleotide-directed mutagenesis

Oligonucleotide-directed mutagenesis was used  
05 to substitute a glutamine residue for the valine  
residue normally found at amino acid position 664.  
When this mutated neu gene was inserted into an  
expression vector and transfected into or infected  
into recipient cells, 100% of the stable cell lines  
10 generated were transformed. (In contrast, 0.1% of  
recipient cells transformed with the normal neu gene  
(proto-oncogene), which encodes a protein including  
a valine residue at amino acid position 664, were  
transformed.) Thus, like glutamic acid, glutamine  
15 at position 664 leads to generation of a trans-  
forming neu gene, and mutations detected with a  
nucleic acid probe that would recognize glutamine  
would be presumed to be transforming mutations.  
Substitution of an aspartic acid residue at position  
20 664, followed by transfection or infection into  
nontransformed cells, led to the transformed pheno-  
type in 2-3% of the recipient cells. This appears  
to represent a weakly transforming allele of the neu  
gene, whose overexpression must be coupled to the  
25 mutation for transformation to occur.

C. Identifying the activation mutation in  
human neu genes

Although the discussion to this point, as well  
as the experimental work described, has been related

to the point mutation responsible for activation of the rat neu oncogene, it is possible to use the same approach in identifying the corresponding activation mutation in human neu genes and in detecting the presence of a neu oncogene (or its corresponding proto-oncogene) in human tumor cell DNAs. For example, nucleic acid probes can be constructed which are specifically reactive with the region of a human neu gene which corresponds to the region shown to contain the point mutation responsible for the activation of the rat neu oncogene. An example of a probe which can be constructed is one based on a single nucleotide difference between a neu oncogene and its proto-oncogene, this single nucleotide alteration being responsible for conversion of the neu proto-oncogene into its activated oncogene form. These probes, which can be of any length, but will generally be 15 to 20 nucleotides long, can then be used to analyze a tumor cell genome, to determine whether it carries lesions (mutations) in the neu oncogene and to determine their precise location, as described above for the rat neu oncogenes.

D. Detecting the presence of a neu oncogene

An assay for detecting carcinogenesis caused by mutation of a neu proto-oncogene into neu oncogene comprises employing a labelled nucleic acid probe specific for a nucleotide sequence present in (or transcribed from) the proto-oncogene or the oncogene, but not the other. An assay for carcinogenesis in human cells can be performed by isolating

-43-

DNA from the test cells and contacting the DNA with a labelled polynucleotide probe specific for either an oncogenic or protooncogenic sequence in the DNA and thereafter determining whether the probe hybridizes to the DNA. After being radiolabelled, these probes can be used, for example, in the Southern blot procedure to assess tumor cell DNAs for the occurrence of such point mutations. This type of assay can be used in a clinical context as a diagnostic tool to determine the profile of oncogenes activated in human tumor DNAs. The assay would be highly specific because it is capable of detecting single nucleotide alterations in genes of the neu family, thus providing very definitive information about the tumor cells being assayed.

Reagents for employing these probes can be assembled into a kit. Thus, a kit might contain, in addition to the probe, one or more buffers, reagents for labelling the probe, reagents employed in Southern or other blots, etc.

Because of the change in amino acid sequence of the product protein encoded by a proto-oncogene from the product encoded by an oncogene, it is possible to detect either by specific serological reagents. The serological reagents can be specific for the normal, neu proto-oncogene-specified amino acid sequence at this site of the protein, or be specific for the altered oncogene-specified amino acid sequence at this site of the protein. Other serological reagents could be employed that are reacted with a region of the protein that is unaltered, and

consequently reactive with either normal or abnormal forms of the encoded protein.

Using cloning techniques, significant amounts of the protein encoded for by the normal site of the  
05 proto-oncogene, or by the altered site of the oncogene, can be isolated. Such protein segments could be used to produce antibodies by standard antibody production techniques. Thus, for producing polyclonal antibodies, such proteins would be employed  
10 to immunize a host, such as a rabbit or a rat, and antibodies to the protein would be collected from serum obtained from the host.

Alternatively, monoclonal antibodies could be produced employing cells which produce antibodies to  
15 the protein produced by the isolated gene segment in typical fusion techniques for forming hybridoma cells. Basically, these techniques involve the fusing of the antibody-producing cell with a cell having immortality, such as a myeloma cell, to  
20 provide a fused cell hybrid which has immortality and is capable of producing the desired antibody (in this case, an antibody to the normal or altered segment of protein coded for by the isolated gene segment). The hybrid cells are then cultured under  
25 conditions conducive to the production of antibody after which antibody is collected from the cell culture medium. Such techniques for producing monoclonal antibodies have been well described in the literature. See, for example, U.S. Patent Nos.  
30 4,172,124 and 4,196,265, issued to Hilary Koprowski

et al., the teachings of which are hereby incorporated by reference.

Example 5: Cloning of Human neu gene

The human neu gene was cloned from two lambda  
05 gt11 cDNA libraries derived from poly A+ RNA of two  
cervical carcinoma cell lines (SW1710, ME180) both  
of which express high levels of neu RNA. A 1300 bp  
Pst 1 fragment of the rat neu tyrosine kinase domain  
was used as the probe to screen the SW1710 cDNA  
10 library. Two recombinant plaques were identified as  
human neu by restriction analysis and partial  
sequencing. The longer of the two clones contained  
the majority of the neu coding sequence. The  
recombinant sequence starts at nucleotide 849 and  
15 codes for all but the first 225 of the 1255 amino  
acids of the neu protein. The missing region of the  
human neu gene was isolated from the ME180 cDNA  
library using the 5' Eco R1 fragment of the SW1710  
neu cDNA clone as a probe. The subcloned regions of  
20 the two clones and the scheme for the construction  
of a full length human neu gene are shown in Figure  
8.

A. Construction of neu expression vectors

The entire neu coding sequence was cloned into  
25 the expression vectors pLJ (Roberts, et al., 1985,  
J. Virol., 56:404-413) and pMax (obtained from  
Bernard Mathey-Prevot without reservations, shown in  
Figure 9). Both these vectors put the neu gene  
under the transcriptional control of the molony

murine leukemia virus promoter and enhancer (LTR). The pLJ vector also expresses neo<sup>R</sup> from an SV40 promoter.

05           B.   Construction of the Transmembrane point  
                  mutation

          Oligo-directed mutagenesis was carried out using the Amersham site-directed mutagenesis kit as per the manufacturers directions and using the following oligonucleotide:

10           CTGCGGTGGAGGCATTCTG

          the underlined nucleotides are different from the normal human neu allele. The presence of the point mutation was determined by differential hybridization and confirmed by sequence analysis using the  
15 Promega double stranded sequencing kit as per the manufacturers directions.

          C.   Construction of the truncated neu allele

          The pMax vector was restricted with NCO 1, at a unique site in the polylinker, and filled in to  
20 create blunt ends with klenow, as shown in Figure 9. A 12 base pair Sph-I linker (N.E.B. #1115) with the following sequence: CATGCATGCATG was inserted at this site to generate a unique Sph-I site in the polylinker. This particular linker was chosen  
25 because it provides a translation initiation signal (ATG) in all three reading frames. The resulting vector is shown as pMax-Sph in Figure 9. PMax-Sph was restricted at the Sph-I site and at the Xho-I site (both in the polylinker). A Sph-I/Sal-I 2225

base pair fragment containing the neu cDNA from just 5' of the transmembrane region to the 3' end of the gene was isolated from a plasmid (shown as pAbT 565 in Figure 9) containing the entire human neu cDNA.

- 05 The restricted vector and the isolated fragment were ligated together and transformed into the bacterial strain HB101. The resulting plasmid, shown in Figure 9, has been designated pMax delta neu or pAbT 5011.

10 D. Transfection of cells

- Neu expression vectors were transfected into NIH 3T3 cells by the standard calcium phosphate procedure. Briefly, on day 1 cells are plated at  $5 \times 10^5$  per 10 cm tissue culture dish. On day 2 the  
15 cells are refed and 4 hours later the DNA precipitate is added and the cells are incubated for 6 hrs and refed. The following day the cells are split into G418 containing media and incubated for 10-14 days. NIH 3T3 DNA was used as carrier and  
20 pSV-2 neo was used as the selective marker.

E. Isolation of RNA

- Total cellular RNA was isolated by the guanidinium isothiocyanate/CsCl method. When isolating RNA from cells in culture the lysis buffer (4M  
25 guanidinium isothiocyanate, 50 mM Tris-HCl pH 7.5, 10 mM EDTA, 0.5% Sarkosyl, 0.1M BME) was added directly to the tissue culture dishes. When frozen tissue was the starting material the tissue was homogenized directly in the lysis buffer with a



tissue homogenizer (Biospec Products, INC.). The cellular lysate is then passed through a 18 gauge needle and layered on a 1.2 ml cushion of 5.7 M CsCl in 0.1 M EDTA in a SW50.1 Beckman pollyallomar tube. 05 Centrifuge at 35,000 rpm for at least 12 hours. The RNA pellet is then resuspended in TE containing 1% SDS.

#### F. Hybridization probe

The 1.6 kb Eco RI fragment containing a portion 10 of the extracellular domain, the transmembrane domain and a small portion of the tyrosine kinase domain was subcloned into Promega's pGEM dual transcription vectors as shown in Figure 10. Label- 15 led RNA transcripts to be used as hybridization probes were generated according to the manufacturers directions.

#### G. RNA slot blot analysis

RNA samples were diluted to 1 ug/ml in 6 X SSC, 7.4% formaldehyde and heated at 65°C for 15 min., 20 then placed on ice. The slot blots were done using the SSS slot blot apparatus and the precut BA 85 nitrocellulose sheets supplied according to the manufacturers directions. The filter was prewet with water and then 10 X SSC and the RNA was added 25 as a series of 2 fold dilutions starting at 200ng/slot in a volume of 200ul. The slots were then washed with 200 ul 10 X SSC and the filter was baked for 2 hours at 80°C in a vacuum oven. The filter was then wet with 10 X SSC and prehybridized

for 2 hours in hybridization buffer (50% formamide, 5 X SSC, 50 mM Sodium Phosphate, 250 ug/ml; salmon sperm DNA, 5 X Denhardt's). The hybridization solution was then replaced with fresh solution containing  $1-2 \times 10^6$  cpm/ml denatured  $^{32}\text{P}$  labelled RNA probe specific to human neu. The filters were then incubated overnight at 65°C. The following morning the filters were washed 3X in 0.1 X SSC, 0.1% SDS for 20 minutes at 80°C.

10 H. Cloning of human neu alleles and testing transforming activity

Two cDNA libraries made from cervical carcinoma cell line RNA that express high levels of neu RNA were screened with a probe derived from the tyrosine kinase domain of the rat neu cDNA. Comparison of restriction maps and partial sequence data with published data confirmed the identity of the intact human neu clone constructed from the original isolates from this screen. The human neu cDNA was then transferred into an LTR driven expression vector. Cells transfected with this human neu construct expressed a 185,000 dalton protein that was indistinguishable from the authentic human neu expressed by the human mammary carcinoma cell line, SKBR-3. When this normal human neu clone (pMax neu shown in Figure 10) was transfected into NIH 3T3 cells they became transformed. This is in direct contrast with the data described for the rat neu gene. In the rat, no matter what the expression level, the normal rat neu allele was not

transforming. Expression of the normal human neu gene in other expression vectors which expressed neu at lower levels did not lead to transformation of the NIH 3T3 cells. However, if the human neu gene  
05 was mutated so the homologous amino acid to the valine in rat neu was changed to glutamic acid, this gene transformed cells in either expression vector. This indicates, that the mutation activates the transforming activity of the human neu gene.  
10 Expression of the truncated human neu allele in either expression vector also transforms NIH 3T3 cells. These results are identical to those reported by Di Fiori, et al. Science, 1987; 237:178-182. In summary, both normal and mutated  
15 human neu alleles can transform NIH 3T3 cells although much higher expression levels are required for the normal neu.

I. Analysis of neu RNA levels in Human cell lines and mammary tumors

20 Total cellular RNA was isolated from a variety of human cell lines and mammary tumors by the guanidium isothiocyanate method. The RNA was then subject to slot blot analysis using a human neu specific probe, the 1.6 kb Eco R1 fragment which  
25 contains a portion of the extracellular domain, the transmembrane domain and part of the tyrosine kinase domain. All RNA samples were also hybridized with a alpha tubulin probe to normalize for the amount of RNA present on the filters. The human mammary cell  
30 line HBL 100 (ATCC HTB 124) was used as a standard

and all results are relative levels as compared to HBL 100. E. Gaffney, Cell Tissue Res., 229:563-568 (1982). The neu expression levels varied from between 1 to 64 times the HBL 100 levels. These 05 results are shown in Table 1.

-52-

Table 1Expression Levels of Neu-Specific RNA in  
Various Cell Lines

	<u>Human Cell Lines</u>	<u>Neu Levels</u>
05	HBL-100	1X
	ME180	8X
	SW1710	4X
	MKN-7	32X
10	SK-BR-3	64X
	A-431	1-2X
	BT-483	8X

Transfected Mouse Line

18-3-7	++++
NIH3T3	1X

- 15 HBL-100 is an epithelial cell line derived from the milk of a nursing mother.  
 ME180 is a cervical carcinoma cell line.  
 SW1710 is a cervical carcinoma cell line.  
 MKN-7 is a gastric cancer cell line.
- 20 SK-BR-3 is an adenocarcinoma of the breast.  
 A-431 is an epidermoid carcinoma cell line.  
 BT-483 is a ductal carcinoma of the breast.

18-3-7 are NIH3T3 cells transfected with neu.  
The results were similar to those previously published (Kraus, et al., EMBO, 1987; 6:605-610). We have also analyzed the neu RNA levels in a series of  
05 primary human mammary carcinomas. Again we find a wide range of neu expression levels ranging from less than 1 to 128 times the standard, as shown Table 2.

Table 2

Quantitation of Neu-Specific RNA levels from  
Mammary Tumor Samples

	<u>Sample</u>	<u>Neu RNA Level</u>
05	1. 6-8-6-86	128
	2. 8-11-20-86	64
	3. 6-10-15-86	16
	4. 5-11-13-86	16
	5. 9-9-10-86	16
10	6. 12-9-12-86	8
	7. 5-10-10-86	8
	8. 8-8-7-86	8
	9. 1-7-7-87	8
	10. 5-9-3-86	4
15	11. 4-2-4-87	4
	12. 6-6-12-87	2
	13. 12-12-17-86	2
	14. 13-9-15-86	2
	15. 21-2-27-87	2
20	16. 4-12-5-86	1/2
	17. 11-12-15-86	1/8
	18. 10-1-23-87	1/8

Hybridization results were determined by serial dilutions of total cellular RNA in dot blot hybridization analysis using the  $^{32}\text{P}$  neu probe. Numbers have been normalized for total RNA amount by hybridization with tubulin probe. Levels are relative to the normal mammary cell line HBL-100 which is set at 1X.

As above, the levels are expressed as relative levels compared to HBL 100 and normalized for tubulin expression.

Example 6: Production of neu-specific monoclonal antibodies

Production Of Hybridomas

The hybridomas described below were generated by immunization of mice with viable cells (the 18-3-7 cell line described below) which express the full length protein encoded by the neu oncogene. This is an important distinction from other approaches for the generation of monoclonal antibodies. Using the full length protein presented by viable cells as the immunogen, it is possible to generate a collection of monoclonal antibodies with specificities that span the entire length of the extracytoplasmic domain of the protein. This is as opposed to the use of peptide immunogens, or short polypeptides generated by prokaryotic systems, which present only a limited number of epitopes from the original protein, and hence raise an immune response of limited specificities. Furthermore, by



presenting the protein antigen in its native state, the immune system will be responding to an antigen which most closely resembles that which will be seen when the antibodies are later used for diagnostic or  
05 therapeutic applications.

B. Generation Of 18-3-7 Cells

18-3-7 cells are a transfected NIH 3T3 cell line that express full length normal human neu at levels equal to or greater than the human mammary  
10 carcinoma cell line, SKBR-3. The human neu gene is expressed by a Murine leukemia virus LTR (promoter and enhancer). This cell line exhibits all the characteristics of transformed NIH 3T3 cells. They grow in soft agar, form tumors in nude mice and  
15 display altered morphological characteristics. This cell line was used as the immunogen for the isolation of anti-neu specific monoclonal antibodies.

The pLJ retroviral vector was modified to remove the polyoma early region, thereby eliminating  
20 the endogenous transforming activity of the pLJ vector. Construction of the modified vector is shown in Figure 11. The modification was accomplished by restricting pLJ with Apa I and isolating the 6300 base pair fragment, and re-  
25 circularizing it with T<sub>4</sub> ligase. The resulting plasmid (pdelta LJ or AbT 5009, shown in Figure 11) was digested at the unique Bam HI site, filled in with Klenow, and ligated to a NcoI-HindIII filled in fragment containing the entire human neu protein  
30 coding region. The resulting plasmid (pdelta LJ neu

or pAbT 577, shown in Figure 11) was transfected into NIH 3T3 cells by the calcium phosphate precipitation procedure. Transfected cells were selected in G418 (pdelta LJ has a SV40 promoted neo<sup>R</sup> gene). The colonies were screened for neu expression by RNA dot blots. 18-3-7 was one of highest expressors out of approximately 50 screened.

### C. Immunization of Mice

Two adult female Balb/c mice were immunized intraperitoneally (I.P.) with  $1.4 \times 10^6$  viable NIH3T3 cells per animal. This was followed immediately by an I.P. injection of cyclophosphamide in H<sub>2</sub>O, 30 mg/kg. The cyclophosphamide treatment was repeated 24 and 48 hours after the primary injection. On day 14 following immunization, the mice were injected I.P. with  $1.5 \times 10^6$  viable 18-3-7 cells. The animals were allowed to rest for another 14 days, at which time the entire sequence of injecting NIH3T3 cells, cyclophosphamide, and 18-3-7 cells was repeated. Four days following the second injection of 18-3-7 cells, the animals were sacrificed and their spleens obtained for the first fusion. A second, identical experiment was performed, in four female Balb/c mice and four female CB6 (Balb/c X C57BL/6) mice, using  $1.8 \times 10^6$  NIH3T3 cells, and  $4.8 \times 10^6$  18-3-7 cells per mouse in the first round, and  $8.5 \times 10^6$  NIH3T3 cells and  $2.7 \times 10^6$  18-3-7 cells in the second round of immunizations.

#### D. Hybridoma Methodology

Hybridomas were produced by fusing cells from immunized mice with SP2/O myeloma cells (ATCC CRL 1518) by a polyethylene glycol (PEG) method.

- 05 Splens were removed aseptically from immunized mice, and a single cell suspension of the spleen cells was obtained by perfusing the spleen with serum-free media (DME). Spleen cells and SP2/O cells (harvested from a log phase growth culture)
- 10 were mixed together at a ratio of 5:1, spleen cell:myeloma cell. The cells were centrifuged at 200 X g for 10 minutes at 4°C, and the supernatant removed by aspiration. After loosening the cell pellet by gently tapping the bottom of the tube, 1
- 15 ml of sterile, 37°C, 10% PEG in DME was added dropwise. The tube was gently swirled while adding the PEG over a 1.5 minute period. An additional 10 ml of 37°C serum-free DME was then added dropwise, followed by another 20 ml of media. The suspension
- 20 was then centrifuged at 200 X g for 10 minutes at room temperature. Media was aspirated from the cell pellet, and media containing peritoneal macrophages ( $2 \times 10^4$  cells per ml) in the presence of 20% fetal calf serum, 0.2 mM hypoxanthine, 0.4 uM aminopterin,
- 25 and 0.032 mM thymidine (HAT media) was used to resuspend the cell pellet. (Peritoneal macrophages were obtained from unimmunized mice, either Balb/c or CB6, depending on which spleen cells were used for fusion. These cells were obtained by injecting
- 30 and immediately removing serum-free media into the peritoneum of euthanized animals.) The post-fusion

cells were resuspended to a final cell concentration (not including the peritoneal macrophages) of  $5 \times 10^5$  cells/ml. One milliliter of this cell mixture was distributed to each well of 24 well plates.

05      E. ELISA Procedure and Preliminary Screening

Hybridomas which grew after the fusion procedure were initially screened for the secretion of anti-neu antibodies by an ELISA assay on a cell lysate of 18-3-7 cells. Lysates were prepared by  
10 incubating freshly harvested 18-3-7 cells in the presence of a hypotonic lysis buffer (10 mM Tris, 10 mM KCl, 5 mM EDTA, pH 8.0) followed by the addition of Triton X 100 to a final concentration of one percent. A lysate of NIH3T3 cells was prepared  
15 similarly for use as a negative control. Microtiter plates (Nunc, Immunoplate II) were coated overnight at room temperature with 50 ul of lysate, at a total protein concentration of 500 ug/ml. After aspirating to remove unbound antigen, ELISA's were  
20 performed by first incubating 50 ul of culture supernatant obtained from the viable hybridoma colonies in the antigen-coated microtiter wells. A 3 hour incubation at 37°C was followed by 3 washes with a washing buffer (0.5% Tween 20, 20 mM Tris, pH  
25 7.6) and then a one hour incubation at 37°C with 50 ul horseradish peroxidase labelled goat anti-mouse IgG + IgA + IgM (HRP-GAM-GAM). The wells were again washed three times with washing buffer, and the assay was developed by the addition of 50 ul of a  
30 tetramethylbenzidine (TMB) solution. This solution

-60-

was prepared by dissolving 10 mg of TMB in 1 ml of dimethylsulfoxide (DMSO), and adding 100 ul of this solution to 5 ml of TMB buffer (0.1 M sodium acetate, to pH 6.0 with 0.1 M citric acid) along with  
05 the addition of 10 ul of 3% hydrogen peroxide. Color was allowed to develop for 5 minutes, at which time the enzymatic reaction was stopped by adding 50 ul of 2 N H<sub>2</sub>SO<sub>4</sub>. The optical density (OD) of the resulting yellow color was read at 450 nm on a  
10 microtiter plate reader. A positive reaction, as indicated by a greater yellow color developed on 18-3-7 cell-coated wells than on NIH3T3 cell-coated wells, signaled that there was antibody present in the culture supernatant which recognized the neu  
15 oncogene product.

#### F. Subcloning Hybridomas

Hybridomas which yielded positive results upon initial screening were expanded and cloned by limiting dilution to assure that the cells and  
20 resulting antibodies were indeed monoclonal. A feeder cell population was first prepared by obtaining thymocytes from 6 week old unimmunized mice, and making a single cell suspension at a concentration of  $2 \times 10^4$  cells/ml in HAT media. Hybridoma  
25 colonies which tested positive for the presence of antibody to the neu gene product were diluted in the media containing thymocytes to a concentration of 5 hybridoma cells/ml. Two hundred microliters of this solution was then delivered to each well of 96 well  
30 microtiter plates. Once colonies had grown, the

supernatants were again tested for the presence of antibody to the neu oncogene product. If the results were positive when tested by the ELISA assay as described above, the colonies were cloned by  
05 limiting dilution a second time.

Hybridomas which were obtained in the manner described above following the first fusion secrete monoclonal antibodies which have been designated BD5-2d, TA1-1c, RC1-4c, NA3-6a, and OD3-10j.  
10 Following the second fusion, hybridomas were obtained which secrete antibodies named PB3, RC6-2, NB3, ID5, and IB3-4.

#### G. Antibody Isotype and Subclass Determination

ELISA assays were performed to determine the  
15 isotype and light chain class of the antibody produced by the hybridomas, and to determine the IgG subclass. For this purpose, a kit was purchased from Boehringer Mannheim (Indianapolis, IN) which contained all of the necessary immunoreagents.  
20 Tissue culture supernatants obtained from the cloned hybridoma colonies were incubated on lysates of 18-3-7 cells as described above. This was followed by an incubation with goat antisera specific for mouse immunoglobulin isotypes, light chain classes,  
25 and IgG subclasses, and then with horseradish peroxidase labelled swine anti-goat IgG as the second antibody. The assay was developed using ABTS (2,2'-azino-bis-[3-ethylbenzthiazoline-6-sulfonic acid]) as per the manufacturer's instructions, and

the OD of the resulting green color was read at 405 nm.

Using this method, it was determined that 3 of the monoclonal antibodies from the first fusion, 05 BD5-2d, RC1-4c, and TA1-1c, are IgG<sub>1</sub>/kappa antibodies, and NA3-6a, and OD3-10j are IgM/kappa antibodies. The monoclonal antibodies RC6-2, NB3, ID5, and IB3-4 obtained from the second fusion are IgG<sub>1</sub>/kappa and the antibody PB3 is IgG<sub>2a</sub>/lambda.

#### 10 H. Radioimmunoprecipitation

Immunoprecipitation of radioactively labelled 18-3-7 cells was done using each of the monoclonal antibodies to determine whether the antibodies recognized a protein of 185 kd molecular weight, the 15 expected molecular weight of the neu oncogene product. A near confluent monolayer of 18-3-7 cells (or NIH 3T3) cells in a 10 cm petri dish was incubated overnight in media containing 500 uCi of <sup>35</sup>S-labelled cysteine. The cells were harvested the 20 following morning, and were lysed in a detergent buffer (IP buffer: 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 10 mM Tris, 0.65 M NaCl, pH 7.2) containing the protease inhibitors PMSF and soybean trypsin inhibitor. Approximately 1 uCi of 25 the labelled cell preparation was then incubated overnight at 4 C with 500 ul of culture supernatant from each of the hybridomas. During this incubation period, 50 ug of purified rabbit anti-mouse IgG (Kirkegaard & Perry Labs) was mixed with 50 ul of a 30 1:1 slurry of Protein A-Sepharose (Pharmacia) in IP

buffer overnight at 4°C. The excess rabbit antibody was removed by washing the Protein A-Sepharose once with IP buffer, and the slurry was then added to the incubation mixture containing the labelled cells and  
05 the monoclonal antibody. This mixture was allowed to react overnight at 4°C. The Protein A-Sepharose was pelleted by centrifugation and was washed four times with IP buffer, followed by one wash with TBS (10 mM Tris, 150 mM NaCl, pH 8.2), and the pellet  
10 was allowed to dry. Each pellet was resuspended in 50 ul of sample buffer for SDS gels (10 mM Tris, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.04% bromphenol blue). One half of each of the samples was run on SDS polyacrylamide gels, using a 4.5%  
15 acrylamide stacking gel, and a 7% separating gel. The gels were dried and then autoradiographed.

Results of the immunoprecipitations indicated that all of the monoclonal antibodies recognized a protein of approximately 185 kd molecular weight in  
20 the 18-3-7 cells which was not present in the NIH 3T3 cells. This was determined by the presence of a dark band on the autoradiograph which corresponded to the distance travelled in the gel by a 185 kd molecular weight protein as indicated by standard  
25 protein markers. A similar experiment was done using SKBR-3 cells (a human breast carcinoma) and A431 cells (a human epidermoid carcinoma). The SKBR-3 cells have been shown by other investigators to express high levels of the human neu oncogene  
30 product, and immunoprecipitations with the monoclonal antibodies described above yielded confirming



results. The band observed migrated the same distance as the band which was precipitated from the labelled 18-3-7 cells. The A431 cell line, on the other hand, is known to express very high levels of the human epidermal growth factor receptor (EGFR), which is a 170 kd protein that has significant homology to the human neu oncogene product in the tyrosine kinase domain of the proteins. This is the one protein which might be cross-reactive with the neu gene product if the antibodies recognize the tyrosine kinase region. However, immunoprecipitation of A431 cells with the monoclonals described above showed no reactivity in the area of 185 kd or 170 kd. A control antibody, specific for human EGFR, did react with a protein in the A431 cells, as expected, and the band observed corresponded to 170 kd molecular weight.

Because there was no reactivity with A431 observed when the monoclonal antibodies raised to the 18-3-7 cells were used, it was concluded that the antibodies were specific for the human neu oncogene product, and did not cross react with the human epidermal growth factor receptor.

Example 7: Detection of p185 neu antigen in biological samples

These Examples illustrate detection of the human neu antigen (approximate molecular weight of 185,000 daltons and referred to as p185) in human fluids such as serum, plasma or urine or in normal preneoplastic or neoplastic cells.

A. Capture Immunoassay

Polystyrene plates (Costar, Cambridge, MA) were coated with either 1 microgram (ug) of an anti-neu monoclonal antibody (Mab), a combination of anti-neu Mabs, or a polyclonal anti-neu antibody for the purpose of capturing the neu antigen from various biological specimens. Mabs were diluted in carbonate buffer (pH = 9.6) and 100 microliters (ul) added to each well of the microtiter plate. The plates were then incubated overnight at 37°C.

After incubation the plates were washed three times with phosphate buffered saline (PBS) with 0.1% bovine serum albumin (BSA). Plates were then incubated with a solution of PBS with 2.5% BSA in order to block sites on the microtiter wells not coated with the anti-neu antibody. Plates were incubated for 1 hour at 37°C and again washed three times with PBS/0.1% BSA. If plates were not used they were stored at 4°C until use.

Specimens to be evaluated for the neu antigen consist of lysates prepared from normal, pre-neoplastic or neoplastic cells or bodily fluids such as serum, plasma or urine. Specimens were incubated with the anti-neu Mabs coated on the microtiter wells in order to capture the neu antigen from the specimen. Specimens were incubated overnight at 25°C. After the overnight incubation, plates were washed 6 times with PBS/0.1% BSA to remove the excess biological specimen.

Another anti-neu Mab labeled with biotin was added to each well for a 1 hour incubation at 37°C.

Plates were washed 6 times with PBS/0.1% BSA. To detect the biotin labeled anti-neu Mab, a strept-  
avidin horseradish-peroxidase solution at a 1:4000  
dilution was added for 1 hour at 37°C. Plates were  
05 washed 6 times with PBS/0.1% BSA. To complete the  
reaction the substrate OPD was added for 15 minutes  
at 37°C. The reaction was stopped with sulfuric  
acid and the optical density was determined using a  
Nunc plate reader in a wavelength of 490 nm.

10        B. Detection of neu from cell and tumor  
              lysates using capture assays

Several capture immunoassays have been per-  
formed to determine usefulness of this assay on  
biological materials. Figure 12 shows the results  
15 of a capture immunoassay in which the first antibody  
is TA-1 and the second antibody is biotinylated  
NA-3. Cell lysates were prepared from several human  
tumor cell lines. Neu RNA levels have been pub-  
lished for several of these cell lines (SK-BR-3,  
20 ZR-75-1, MCF-7). The relative levels of neu antigen  
detected by this assay are in agreement with the  
published RNA data. The results of these assays and  
several others (not shown) using cell lines with  
known levels of neu antigen indicates this assay can  
25 be used to determine the relative level of neu  
antigen in cell lysates. Results also indicate that  
differences in expression of neu antigen can be used  
to classify the carcinoma cell lines shown in Figure  
12.

30        In order to determine if this assay could  
detect neu antigen in tumor lysates, tumors that

either expressed neu (X-3-5) or did not express neu (3T3-ras) were grown in nude mice. The two NIH 3T3 derived cell lines are isogenic except that X-3-5 contains an expressed human neu gene. Figure 13  
05 shows the results of a capture immunoassay using NB-3 as the first antibody and biotinylated TA-1 as the detector antibody. Neu antigen was detected in the lysate of the X-3-5 tumor but in the lysate of the 3T3-ras tumor, indicating the assay can  
10 specifically detect the human neu antigen in tumor lysates.

Several investigators have shown that many human breast tumors express neu at high levels. In order to determine if neu can be detected in human  
15 breast tumors two samples from the same individual were prepared. Lysates were prepared from a human breast tumor (2747-01-050) and from normal breast tissue (2747-01-050) from the same patient. In this assay TA-1 was used as the first antibody and  
20 biotinylated BD-5 was used as the detector antibody. Figure 14 shows that neu can be detected in the tumor but not the normal breast tissue.

These assays show that the neu capture immunoassay can specifically detect human neu from either  
25 cell or tumor lysates. The data also indicate the assay can determine relative levels of neu between samples.

#### C. Detection of neu in blood plasma and sera

These examples illustrate detection of neu  
30 antigen in sera and plasma from mice and humans bearing neoplastic tumors.

In order to determine if neu antigen can be specifically detected in human sera or plasma several control experiments were performed. These include detection of the neu antigen in the culture  
05 supernatant of cell lines that express high levels of neu and in the sera of nude mice bearing tumors.

Figure 15 shows the results of a capture immunoassay of neu from culture supernatants of cell lines using NB-3 as the first antibody and biotinylated TA-1 as the detector antibody. The  
10 results show that neu antigen can be detected in the supernatant of murine (18-3-7) or human (SK-BR-3) cell lines that express high levels of neu but not in the supernatant of a cell line that does not  
15 express neu, 3T3-ras, or in media alone. Two of these cell lines are able to grow as tumors in nude mice (18-3-7 and 3T3-ras). Mice bearing tumors derived from injecting these cell lines subcutaneously into nude mice were bled and their sera  
20 was analyzed for the presence of neu antigen by a capture immunoassay using TA-1 as the first antibody and biotinylated BD-5 as the detector antibody. The results of this assay are shown in Figure 16. As with the cell or tumor lysates and the cell culture  
25 supernatants only the sera of the nude mouse bearing a tumor that expresses neu shows neu antigen in the assay. Both normal nude mouse sera and sera from a nude mouse bearing a tumor that does not express neu show no neu antigen in the sera.

30 These experiments indicate that neu antigen is found in the sera of nude mice bearing tumors

-69-

expressing neu antigen. The neu antigen was found in the supernatant of human cell lines expressing neu (SK-BR-3) as well as the cell line causing the nude mouse tumor.

- 05        Assays were performed that were designed to test the hypothesis that patients with tumors expressing high levels of neu will have sera containing neu antigen. One series of assays used anti-neu Mab TA-1 as the capture reagent and BD-5  
10        labeled with biotin as the detection reagent. Samples for analysis included normal human plasma and plasma from 2 breast carcinoma patients. Results show that normal plasma and plasma from patient AJAC were virtually unreactive in this assay  
15        whereas plasma from patient PSUL showed significant reactivity in this assay suggesting that the p185 antigen was present in the plasma of the breast carcinoma patient PSUL (Figure 17).

- This experiment was repeated on a larger number  
20        of patients with MAb NB-3 as the capture reagent (affixed to the solid support) and MAb TA-1 labeled with biotin as the detection reagent. Using this assay, 37 separate plasma samples were evaluated for reactivity with neu-specific monoclonal antibodies.  
25        The specimens consisted of 12 plasma samples from normal people, 6 plasma samples from individuals with benign breast disease and 19 plasma samples from breast cancer patients. Figure 18 illustrates the average value (units of neu) for the three  
30        groups. Normals and benign have average values between between 100-110 and the 19 breast cancer

patients had neu values that averaged approximately 200. Table 3 presents the individual data obtained for samples. Several neu values from patients with breast cancer exceeded the upper limit of the assay and are designated as "500+" in Table 3. In these cases, samples were further diluted by a factor of 2, and the assays were re-run. Results are shown in parentheses.

05

1

TABLE 3

ELISA Results (neu units) from  
Three Types of Patients

	Patient	Normal	Benign	Cancer
05	1	100	90	210
	2	90	100	210
	3	137	87	500+ (300)
	4	75	70	120
	5	112	102	200
10	6	183	110	500+ (210)
	7	152		175
	8	77		500+
	9	91		142
	10	88		70
15	11	81		60
	12	63		80
	13			90
	14			90
	15			122
20	16			142
	17			160
	18			123
	19			140

Example 8 TA-1 Inhibition of neu Transformed Cells  
in Soft Agar

25

This Example illustrates that anti-neu monoclonal antibodies may have cytostatic effects on transformed cells.



Mouse fibroblasts (NIH3T3 cells) transfected with and expressing high levels of the human neu gene will form colonies in soft agar. This property is directly related to the amount of neu protein and its inherent tyrosine kinase activity. Monoclonal antibodies (MAbs) which recognize the extracellular portion of the human neu protein will cause these proteins to cluster and patch on the cell surface, and then internalize into the cell thereby decreasing the amount of tyrosine kinase activity. We have demonstrated that the addition of the MAb TA-1 to a neu transformed NIH3T3 cell line (17-3-1-3) growing in soft agar will decrease the number of colonies formed by this cell line in a concentration dependent manner. Specifically, at the highest concentration of TA-1 used (150 ug/ml), less than 5% of the expected number of colonies formed (7 colonies compared with the 150 formed on the untreated control group). A nonspecific MAb matched to the same mouse subtype as TA-1 (both IgG<sub>1</sub>) had no effect on the number of colonies formed at 150 ug/ml. This growth inhibitory effect appears to be cytostatic and not cytocidal as the cells which do not form colonies in the soft agar are still viable. This result has obvious implications for antibody directed toxin therapy to tumor cells which over express the human neu protein.

#### Deposit

A deposit was made with the American Type Culture Collection, Rockville, Maryland of the antibody-producing cell line BD5-2d. The ATCC number is HB 9698.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific  
05 embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

-74-

CLAIMS

1. An antibody specific for at least one extracellular domain of a neu gene encoded product. 5
- 05 2. An antibody of Claim 1 which is monoclonal.
3. An antibody of Claim 2 selected from the group consisting of murine monoclonal antibodies BD5-2d, TA1-1c, RC1-4c, NA3-6a, OD3-10j, PB3, RC6-2, NB3, ID5 and IB3-4. 10
- 10 4. A method of tumor immunotherapy comprising administering to a patient afflicted with a tumor which expresses a neu gene encoded product, an anti-tumor amount of an antibody specific for the neu gene encoded product. 15
- 15 5. A method of tumor immunotherapy of Claim 4, wherein the antibody is specific for the extracellular domain of a neu gene encoded product. 20
- 20 6. A method of Claim 4 wherein the antibody or fragment thereof is coupled to a cytotoxic agent. 25
7. A method of Claim 4 wherein the antibody is a chimeric antibody.

8. An assay for detecting the level of cellular expression of neu gene encoded product, comprising:
  - 05 a. contacting antibodies specific for the neu gene product with cells to be tested under conditions appropriate for binding of the antibodies to the neu gene product on the cells; and
  - 10 b. determining the level of antibody binding to the cell as indicative of the level of expression of the neu gene product.
9. A assay of Claim 8, wherein the level of antibody binding to the cell is determined by immunochemical techniques.
- 15 10. An assay of Claim 8, wherein the antibodies are specific for the extracellular domain of a neu gene encoded product.
- 20 11. An assay for detecting the overexpression of the neu gene proto-oncogene or oncogene in biological fluids, comprising:
  - 25 a. contacting polyclonal or monoclonal antibodies specific for the neu gene encoded product with the biological fluid sample under conditions appropriate for reaction of the antibodies with the neu gene encoded product; and
  - b. determining the level of antibody-antigen reaction as indicative of the amount of the neu gene encoded product in the sample.

12. An immunometric assay for human neu antigen in a fluid comprising:
  - a. forming a complex of:
    - 05 i. a first antibody that is specific for an immunogenic region of the neu antigen;
    - ii. a second antibody that is labeled, specific for another immunogenic region of the neu antigen; and
    - 10 iii. the neu antigen;
  - b. detecting the amount of label associated with the complex formed from the components of step (a), as indicative of the quantity of human neu antigen in the fluid.
- 15 13. An assay of Claim 12, wherein the fluid is a biological fluid selected from the group consisting of serum, plasma, urine, normal cell lipate, preneoplastic cell lysate and neoplastic cell lysate.
- 20 14. An assay of Claim 12, wherein the second antibody is labeled with biotin.
15. An assay of Claim 12, wherein the first antibody is affixed to a solid phase before formation of the complex.
- 25 16. An assay of Claim 14, wherein the biotin label is detected by reacting the complex with a streptavidin-horseradish peroxidase solution.

17. An assay of Claim 12, wherein the first and second antibodies are antibodies selected from the group consisting of monoclonal, polyclonal and chimeric antibodies.
- 05 18. An assay for human neu antigen in a human fluid, comprising the steps of:
- a. forming an immunoabsorbent containing a solid phase to which is affixed anti-neu antibodies;
  - 10 b. blocking sites on the immunoabsorbent not affixed with anti-neu antibodies with a solution of phosphate buffered saline and bovine serum albumin;
  - c. separating the immunoabsorbent from the blocking solution of step (b);
  - 15 d. forming an incubation mixture of the immunoabsorbent and human fluid;
  - e. incubating the mixture under conditions and for a period of time sufficient for the neu antigen in the fluid to bind to the immunoabsorbent;
  - 20 f. thereafter separating the immunoabsorbent from the fluid;
  - g. forming an incubation mixture of the immunoabsorbent and soluble labeled anti-neu antibody;
  - 25 h. incubating the immunoabsorbent under conditions and for a period of time sufficient for the anti-neu antigen on the immunoabsorbent;
  - 30 i. removing unbound, unlabeled anti-neu antibody;

- j. detecting the amount of label bound to the immunoadsorbent by adding to the immunoadsorbent of an enzyme solution;
  - k. thereafter incubating the immunoadsorbent in the presence of a suitable enzyme substrate; and
  - l. measuring the optical density of the immunoadsorbent.
- 05
19. An assay of Claim 18, wherein the anti-neu antibodies affixed to the immunoadsorbent are selected from the group consisting of monoclonal antibody TA-1 and NB-3.
- 10
20. An assay of Claim 18, wherein the soluble, labeled anti-neu antibody is labeled with biotin and is selected from the group consisting of monoclonal antibodies TA-1, NA-3 and BD-5.
- 15
21. An assay of Claim 18, wherein the enzyme solution is a solution of streptavidin-horseradish peroxidase and the enzyme substrate is OPD.
- 20
22. An assay of Claim 18, wherein the human fluid is a fluid selected from the group consisting of serum, plasma, urine, normal cell lysate, preneoplastic cell lysate and neoplastic cell lysate.
- 25
23. A nucleic acid probe which is specifically reactive with a nucleotide sequence present in a

neu proto-oncogene or oncogene of mammalian origin.

24. A nucleic acid probe of Claim 23 which is labelled.
- 05 25. A nucleic acid probe of Claim 23 which is radiolabelled.
26. A nucleic acid probe of Claim 23 wherein the nucleic acid is DNA.
- 10 27. A nucleic acid probe which is specifically reactive with a nucleotide sequence present in a neu proto-oncogene or oncogene of mammalian origin, the probe comprising a nucleic acid sequence of a neu gene of about 1.6 kilobases which is complementary to a portion of the  
15 extracellular domain, the transmembrane domain and a portion of the tyrosine kinase domain of a neu gene.
- 20 28. A nucleic acid probe of Claim 27 wherein the probe comprises a 1.6 kilobase Eco RI restriction fragment of a neu gene sequence.
29. A nucleic acid probe of Claim 27 wherein the neu proto-oncogene or oncogene is of human origin.
30. An assay for cancer in mammalian cells, comprising:  
25 a. contacting a nucleic acid from the cells with an nucleic acid probe specific for a



-80-

- 05 nucleotide sequence of the neu proto-oncogene or oncogene, under conditions appropriate for hybridization of the probe with the nucleic acid for which it is specific; and
- b. determining the level of hybridization between the nucleic acid and the probe, as indicative of the presence of cancer in the cells.
- 10 31. A assay of Claim 30 wherein the nucleic acid probe is radiolabelled.
- 15 32. An assay of Claim 30 wherein the nucleic acid probe comprises a nucleic acid sequence of a neu gene of about 1.6 kilobases which is complementary to a portion of the extracellular domain, the transmembrane domain and a portion of the tyrosine kinase domain of a neu gene.
33. An assay of Claim 30 wherein the neu proto-oncogene or oncogene is of human origin.
- 20 34. A method of detecting amplification of a neu proto-oncogene or oncogene in tumor cells, comprising:
- 25 a. isolating DNA from the tumor cells;
- b. contacting the DNA with a nucleic acid probe reactive with a nucleotide sequence present in a neu proto-oncogene or oncogene under conditions appropriate for hybridization of the probe with the DNA for which it is specific; and

- c. determining the level of hybridization between the DNA and the probe, as indicative of DNA amplification of the neu proto-oncogene or oncogene.

- 05    35.    A method of detecting overexpression of a neu  
proto-oncogene or oncogene in tumor cells,  
comprising:
- a.    isolating RNA from the tumor cells;
  - 10    b.    contacting the RNA with a nucleic acid  
probe reactive with a nucleotide sequence  
present in a neu proto-oncogene or oncogene  
under conditions appropriate for  
hybridization of the probe with the nucleic  
acid for which it is specific; and
  - 15    c.    determining the level of hybridization  
between the RNA and the probe, as indica-  
tive of RNA overexpression of the neu  
proto-oncogene or oncogene.

FIG. I






FIG.2B

a b c d e f g h i j  
-+--+--+--+--+--+--+--+--+



p185—

FIG.2A



## FIG.3

normal

glu	gln	arg	ala	ser	pro	val	thr	phe	ile	ile	ala	thr	val	:	gly	val	aa 666
GAG	CAG	AGA	GCC	AGC	CCG	GTG	ACA	TTC	ATC	ATT	GCA	ACT	GTA	:	GGC	GTC	

transforming

leu	leu	phe	leu	ile	leu	val	val	val	val	gly	ile	leu	ile	lys	arg	arg	aa 683
CTG	CTG	TTC	CTG	ATC	TTA	GTG	GTG	GTC	GTT	GGA	ATC	CTA	ATC	AAA	CGA	AGC	

## FIG.4

- A) ACGCCCACTACAGTTGCAAT      nucleotides 1999-2018, wild-type sequence
- \*
- B) ACGCCCTCTACAGTTGCAAT      nucleotides 999-2018, T<sub>2012</sub> to A
- C) CCGTCCTCAGCTGTGACC      nucleotides 996-1013, control probe
- \*
- D) ACGCCCCCTACAGTTGCAAT      nucleotides 1999-2018, T<sub>2012</sub> to G

FIG.5





FIG. 6

a b c d e f g h i j







7/18

# FIG.7

N G B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 cl c2



N G B 1 2 3 4 5 6 7 8 9 10 11 12 13 14 cl c2








Fig. 8

9/18



Construction of pMax neu and pMax delta neu

Fig. 9



Neu Oncogene Probe Design

Fig. 10




Fig. 11




Fig. 12

Detector AB is biotinylated NA3

## NEU CAPTURE ELISA USING MAB NB3





Fig. 13

Detector AB is Biotin labeled TA-1

## NEU CAPTURE OF HUMAN BREAST TISSUE



—▲— Normal breast 2747-01-050


—□— Breast tumor 2747-01-050

Detector AB is Biotin labeled BD-5

*Fig. 14*



# NEU CAPTURE OF CULTURE SUPERNATANTS USING MAB NB3




- 18-3-7
- 3T3-RAS
- △ SKBR3 LOT #2
- ◇ DHEN 10% FCS

Detector AB is biotinylated TA-1

Fig. 15

## NEU CAPTURE USING MAB TA-1



—□— 3T3 (RAS) Mouse  
 ---●--- 18-3-7 Mouse  
 ---▲--- T144 Mouse

Detector AB is Biotinylated BD-5

*Fig. 16*

# NEU CAPTURE OF HUMAN PLASMA USING MAB TA-1





Fig. 17

Detector AB is biotin labeled BD-5

*Fig. 18*

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 89/01636

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>4</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>4</sup> : C 12 Q 1/68, G 01 N 33/574, C 12 N 15/00														
<b>II. FIELDS SEARCHED</b> <div style="text-align: right; font-size: small;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border-bottom: 1px solid black; font-size: small;">Classification System</th> <th style="border-bottom: 1px solid black; font-size: small;">Classification Symbols</th> </tr> <tr> <td style="border-right: 1px solid black; padding: 5px;">IPC<sup>4</sup></td> <td style="padding: 5px;">C 12 Q, C 12 N, G 01 N</td> </tr> </table> <div style="text-align: center; font-size: x-small; margin-top: 5px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup></div>			Classification System	Classification Symbols	IPC <sup>4</sup>	C 12 Q, C 12 N, G 01 N								
Classification System	Classification Symbols													
IPC <sup>4</sup>	C 12 Q, C 12 N, G 01 N													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black; font-size: small;">Category <sup>9</sup></th> <th style="border-bottom: 1px solid black; font-size: small;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="border-bottom: 1px solid black; font-size: small;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">WO, A, 87/07646 (WHITEHEAD INSTITUTE) 17 December 1987 see claims</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-35</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">-- Chemical Abstracts, volume 106, 1987, (Columbus, Ohio, US), J.A. Drebin et al.: "Inhibition of tumor growth by a monoclonal anti- body reactive with an oncogene-encoded tumor antigen", see page 385, abstract 31140g, &amp; Proc. Natl. Acad. Sci. U.S.A. 1986, 83(223), 9129-33</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-22</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">P,X</td> <td style="padding: 5px;">-- Chemical Abstracts, volume 108, 1988, (Columbus, Ohio, US), J.A. Drebin et al.: "Monoclonal antibodies reactive with distinct domains of the neu oncogene- encoded p185 molecule exert synergistic anti-tumor effects in vivo", see page 532, abstract 184829e, &amp; Oncogene 1988, 2(3), 273-7</td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-22</td> </tr> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	X	WO, A, 87/07646 (WHITEHEAD INSTITUTE) 17 December 1987 see claims	1-35	X	-- Chemical Abstracts, volume 106, 1987, (Columbus, Ohio, US), J.A. Drebin et al.: "Inhibition of tumor growth by a monoclonal anti- body reactive with an oncogene-encoded tumor antigen", see page 385, abstract 31140g, & Proc. Natl. Acad. Sci. U.S.A. 1986, 83(223), 9129-33	1-22	P,X	-- Chemical Abstracts, volume 108, 1988, (Columbus, Ohio, US), J.A. Drebin et al.: "Monoclonal antibodies reactive with distinct domains of the neu oncogene- encoded p185 molecule exert synergistic anti-tumor effects in vivo", see page 532, abstract 184829e, & Oncogene 1988, 2(3), 273-7	1-22
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
X	WO, A, 87/07646 (WHITEHEAD INSTITUTE) 17 December 1987 see claims	1-35												
X	-- Chemical Abstracts, volume 106, 1987, (Columbus, Ohio, US), J.A. Drebin et al.: "Inhibition of tumor growth by a monoclonal anti- body reactive with an oncogene-encoded tumor antigen", see page 385, abstract 31140g, & Proc. Natl. Acad. Sci. U.S.A. 1986, 83(223), 9129-33	1-22												
P,X	-- Chemical Abstracts, volume 108, 1988, (Columbus, Ohio, US), J.A. Drebin et al.: "Monoclonal antibodies reactive with distinct domains of the neu oncogene- encoded p185 molecule exert synergistic anti-tumor effects in vivo", see page 532, abstract 184829e, & Oncogene 1988, 2(3), 273-7	1-22												
<div style="font-size: x-small;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; font-size: small;">Date of the Actual Completion of the International Search</td> <td style="width: 50%; border-bottom: 1px solid black; font-size: small;">Date of Mailing of this International Search Report</td> </tr> <tr> <td style="text-align: center; padding: 5px;">11th August 1989</td> <td style="text-align: center; padding: 5px;">03. 10. 89</td> </tr> <tr> <td style="border-bottom: 1px solid black; font-size: small;">International Searching Authority</td> <td style="border-bottom: 1px solid black; font-size: small;">Signature of Authorized Officer</td> </tr> <tr> <td style="text-align: center; padding: 5px;">EUROPEAN PATENT OFFICE</td> <td style="text-align: center; padding: 5px;"> <div style="font-size: large; font-weight: bold; margin-top: 5px;">T.K. WILLIS</div> </td> </tr> </table>			Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	11th August 1989	03. 10. 89	International Searching Authority	Signature of Authorized Officer	EUROPEAN PATENT OFFICE	<div style="font-size: large; font-weight: bold; margin-top: 5px;">T.K. WILLIS</div>				
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report													
11th August 1989	03. 10. 89													
International Searching Authority	Signature of Authorized Officer													
EUROPEAN PATENT OFFICE	<div style="font-size: large; font-weight: bold; margin-top: 5px;">T.K. WILLIS</div>													

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X	Science, volume 235, 9 January 1987, D.J. Slamon et al.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene", pages 177-182 see the whole article --	23-35
X	Chemical Abstracts, volume 107, 1987, (Columbus, Ohio, US), M. Van de Vijver et al.: "Amplifi- cation of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene", see page 177, abstract 1863y, & Mol. Cell. Biol. 1987, 7(5), 2019-23 --	23-35
A	EP, A, 0108564 (REGENTS OF UNIVERSITY OF CALIFORNIA) 16 May 1984 see claims 1-30 -----	1-35

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

US 8901636

SA 28594

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 22/09/89  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WI-A- 8707646		None	
EP-A- 0108564	16-05-84	AU-B- 559912	26-03-87
		AU-A- 2065083	10-05-84
		CA-A- 1252046	04-04-89
		DE-A- 3376507	09-06-88
		JP-A- 59113898	30-06-84
		US-A- 4699877	13-10-87

FIG FORM 1009

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☒ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☒ Claim numbers 4-7... because they relate to subject matter not required to be searched by this Authority, namely:

- See PCT Rule 39.1(iv) Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claim numbers..... because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers..... because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 8.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.  
☐ No protest accompanied the payment of additional search fees.